

# 2022 PRIOR AUTHORIZATION CRITERIA

## TABLE OF CONTENTS

Abiraterone Acetate.....	169
Abraxane.....	109
Actimmune.....	10
Adcetris.....	109
Adempas.....	157
Alecensa.....	169
Aliqopa.....	109
Alosetron Hydrochloride.....	11
Alunbrig.....	169
Alymsys.....	109
Ambrisentan.....	159
Androderm.....	17
Apokyn.....	22
Apomorphine.....	22
Arcalyst.....	23
Aripiprazole.....	20
Aripiprazole Odt.....	20
Armodafinil.....	24
Arranon.....	109
Arzerra.....	109
Asenapine Maleate Sl.....	20
Avastin.....	109
Avita.....	193
Ayvakit.....	169
Balversa.....	169
Bavencio.....	136
Beleodaq.....	109
Benlysta IV.....	27
Benlysta SC.....	28
Benzotropine Mesylate.....	103
Besponsa.....	109
Besremi.....	169
Betaseron.....	127
Bexarotene.....	169
Bexarotene (Topical).....	187
Blenrep.....	109
Blincyto.....	109
Bortezomib.....	109
Bosulif.....	169
Braftovi.....	169

Brukinsa .....	169
Cabometyx .....	169
Calquence.....	169
Caplyta.....	20
Caprelsa .....	169
Carglumic .....	64
Cerezyme .....	91
Chenodal.....	65
Chlorpromazine Hcl.....	20
Chlorpromazine Hydrochloride .....	20
Chorionic Gonadotropin .....	66
Cinacalcet Hydrochloride .....	67
Clemastine Fumarate .....	103
Clobazam .....	29
Clorazepate Dipotassium .....	30
Clovique .....	195
Clozapine.....	20
Clozapine Odt.....	20
Cometriq.....	169
Copaxone .....	129
Copiktra .....	169
Corlanor.....	69
Cosentyx .....	34
Cosentyx Sensoready Pen .....	34
Cotellic.....	169
Cresemba .....	70
Crysvita .....	71
Cyclobenzaprine Hydrochloride .....	104
Cyramza .....	109
Cystadrops.....	73
Cystagon .....	75
Cystaran.....	74
Dalfampridine Er.....	76
Daliresp.....	167
Danazol.....	13
Danyelza .....	109
Darzalex.....	109
Darzalex Faspro.....	109
Daurismo.....	169
Deferasirox (Exjade).....	112
Deferasirox (Jadenu) .....	113
Diazepam .....	31
Diclofenac Sodium .....	191
Dicyclomine Hydrochloride .....	103
Dimethyl Fumarate.....	128
Dimethyl Fumarate Starterpack .....	128
Doxorubicin Hydrochloride Liposome .....	109
Droxidopa PA .....	77

Dupixent .....	78
Ellelyso .....	93
Eligard.....	117
Emgality.....	81
Empliciti .....	109
Enbrel .....	36
Enbrel Mini .....	36
Enbrel Sureclick.....	36
Enhertu.....	109
Epclusa.....	82
Epidiolex .....	83
Erbitux .....	109
Erivedge.....	169
Erleada.....	169
Erlotinib Hydrochloride .....	169
Everolimus.....	169
Everolimus Oral Suspension Tablet.....	169
Exkivity.....	169
Fanapt .....	20
Fanapt Titration Pack .....	20
Farydak.....	169
Fentanyl.....	144
Fentanyl Citrate Oral Transmucosal.....	86
Fintepla.....	87
Fluphenazine Decanoate.....	20
Fluphenazine Hcl .....	20
Fluphenazine Hydrochloride .....	20
Folotyng.....	109
Fotivda.....	169
Fulvestrant .....	109
Gamunex-C.....	88
Gattex.....	90
Gavreto.....	169
Gazyva.....	109
Gilotrif .....	169
Glydo .....	118
Granix.....	68
Haegarda.....	99
Halaven.....	109
Haloperidol.....	20
Haloperidol Decanoate.....	20
Haloperidol Lactate.....	20
Harvoni .....	101
Herceptin .....	109
Herceptin Hylecta .....	109
Herzuma.....	109
Hetlioz .....	102
Humira.....	38

Humira Pediatric Crohns Disease Starter Pack.....	38
Humira Pen.....	38
Humira Pen-Cd/Uc/Hs Starter.....	38
Humira Pen-Pediatric Uc Starter Pack.....	38
Humira Pen-Ps/Uv Starter.....	38
Ibrance.....	169
Icatibant Citrate.....	100
Iclusig.....	169
Idhifa.....	169
Ilaris.....	106
Imatinib Mesylate.....	169
Imbruvica.....	169
Imfinzi.....	137
Imiquimod.....	108
Inlyta.....	169
Inqovi.....	169
Inrebic.....	169
Iressa.....	169
Jakafi.....	169
Jemperli.....	138
Jevtana.....	109
Kadcyla.....	109
Kalydeco.....	114
Kanjinti.....	109
Kerendia.....	115
Keytruda.....	139
Kisqali.....	169
Kisqali Femara 200 Dose.....	169
Kisqali Femara 400 Dose.....	169
Kisqali Femara 600 Dose.....	169
Korlym.....	116
Koselugo.....	170
Kyprolis.....	109
Lapatinib Ditosylate.....	170
Lenalidomide.....	170
Lenvima 10 Mg Daily Dose.....	170
Lenvima 12Mg Daily Dose.....	170
Lenvima 14 Mg Daily Dose.....	170
Lenvima 18 Mg Daily Dose.....	170
Lenvima 20 Mg Daily Dose.....	170
Lenvima 24 Mg Daily Dose.....	170
Lenvima 4 Mg Daily Dose.....	170
Lenvima 8 Mg Daily Dose.....	170
Leuprolide Acetate.....	117
Libtayo.....	140
Lidocaine.....	119
Lidocaine Hcl.....	118
Lidocaine Hcl Jelly.....	118

Lidocaine Hydrochloride .....	120
Lidocaine/Prilocaine .....	121
Linezolid.....	122
Lonsurf.....	170
Lorazepam.....	32
Lorbrena.....	170
Loxapine.....	20
Lumakras.....	170
Lumoxiti .....	109
Lupron Depot (1-Month).....	117
Lupron Depot (3-Month).....	117
Lupron Depot (4-Month).....	117
Lupron Depot (6-Month).....	117
Lupron Depot-Ped (1-Month) .....	117
Lupron Depot-Ped (3-Month) .....	117
Lybalvi.....	20
Lynparza.....	170
Margenza .....	109
Matulane.....	170
Megestrol Acetate .....	105
Mekinist .....	170
Mektovi.....	170
Memantine Hcl Titration Pak .....	124
Memantine Hydrochloride .....	124
Miglustat.....	184
Modafinil.....	125
Molindone Hydrochloride .....	20
Monjuvi.....	109
Morphine Sulfate Er .....	145
Movantik.....	126
Mvasi.....	110
Mylotarg .....	110
Natpara.....	132
Nelarabine.....	110
Nerlynx .....	170
Nexavar.....	170
Ninlaro.....	170
Nubeqa .....	170
Nuedexta.....	133
Nuplazid.....	134
Octreotide Acetate .....	175
Odomzo .....	170
Ofev.....	135
Ogivri.....	110
Olanzapine .....	20
Olanzapine Odt .....	20
Omnitrope.....	97
Onivyde.....	110

Ontruzant.....	110
Onureg.....	170
Opdivo .....	141
Opsumit .....	161
Oralair.....	146
Orgovyx.....	170
Orkambi .....	147
Oxandrolone .....	14
Padcev .....	110
Paliperidone Er.....	20
Panretin .....	148
Paroxetine Hcl.....	105
Paroxetine Hydrochloride .....	105
Paxil.....	105
Pegasys .....	149
Pegasys Proclick.....	149
Pemazyre .....	170
Pemetrexed.....	110
Perjeta .....	110
Perphenazine.....	20
Phesgo.....	110
Pimecrolimus .....	25
Piqray 200Mg Daily Dose .....	170
Piqray 250Mg Daily Dose .....	170
Piqray 300Mg Daily Dose .....	170
Pirfenidone .....	85
Polivy .....	110
Pomalyst .....	170
Portrazza.....	110
Posaconazole.....	150
Poteligeo.....	110
Pregnyl W/Diluent Benzyl Alcohol/Nacl.....	66
Prolastin-C.....	12
Prolia .....	152
Promacta.....	155
Promethazine Hcl .....	103
Promethazine Hcl Plain.....	103
Promethazine Hydrochloride.....	103
Qinlock.....	170
Quetiapine Fumarate .....	20
Renflexis.....	40
Repatha .....	165
Repatha Pushtronex System.....	165
Repatha Sureclick .....	165
Retacrit.....	84
Retevmo.....	170
Revlimid.....	170
Rexulti.....	20

Riabni .....	42
Rinvoq .....	44
Risperidone .....	20
Risperidone Odt .....	20
Rituxan.....	46
Rituxan Hycela .....	48
Romidepsin.....	110
Rozlytrek.....	170
Rubraca.....	170
Ruxience .....	50
Rybrevant.....	110
Rydapt .....	170
Sajazir.....	100
Sapropterin Dihydrochloride .....	168
Sarclisa.....	110
Scemblix.....	170
Secuado .....	20
Signifor .....	173
Sildenafil Citrate.....	163
Sivextro.....	174
Skyrizi .....	52
Skyrizi Pen .....	52
Sodium Phenylbutyrate .....	198
Somatuline Depot.....	177
Somavert.....	179
Sorafenib.....	170
Spravato 56Mg Dose.....	180
Spravato 84Mg Dose.....	180
Sprycel .....	170
Stelara .....	54
Stivarga.....	170
Strensiq.....	182
Sunitinib Malate .....	170
Symdeko .....	186
Sympazan.....	33
Synribo.....	110
Tabrecta.....	170
Tacrolimus.....	26
Tafinlar.....	170
Tagrisso.....	170
Talzenna.....	171
Tasigna.....	171
Tazarotene .....	192
Tazorac .....	192
Tazverik.....	171
Tecentriq.....	142
Tepmetko.....	171
Testosterone.....	17

Testosterone Cypionate.....	15
Testosterone Pump.....	17
Tetrabenazine.....	189
Thalomid.....	171
Thioridazine Hcl.....	20
Thiothixene.....	20
Tibsovo.....	171
Tobramycin.....	190
Trazimera.....	110
Trelstar Mixject.....	194
Tretinoin (Topical).....	193
Tretinoin Capsule.....	171
Trientine Hydrochloride.....	195
Trifluoperazine Hcl.....	20
Trikafta.....	196
Trodelvy.....	110
Truseltiq.....	171
Truxima.....	56
Tukysa.....	171
Turalio.....	171
Tymlos.....	197
Tysabri.....	130
Unituxin.....	110
Vectibix.....	110
Velcade.....	110
Venclexta.....	171
Venclexta Starting Pack.....	171
Versacloz.....	20
Verzenio.....	171
Vitrakvi.....	171
Vizimpro.....	171
Vonjo.....	171
Voriconazole.....	199
Vosevi.....	201
Votrient.....	171
Vpriv.....	95
Vyndaqel.....	202
Vyxeos.....	110
Wakix.....	203
Welireg.....	171
Xalkori.....	171
Xeljanz Solution.....	58
Xeljanz Tablet.....	60
Xeljanz Xr.....	62
Xgeva.....	204
Xifaxan.....	206
Xolair.....	207
Xospata.....	171



Xpovio.....	171
Xpovio 100 Mg Once Weekly .....	171
Xpovio 40 Mg Once Weekly .....	171
Xpovio 40 Mg Twice Weekly .....	171
Xpovio 60 Mg Once Weekly .....	171
Xpovio 60 Mg Twice Weekly .....	171
Xpovio 80 Mg Once Weekly .....	171
Xpovio 80 Mg Twice Weekly .....	171
Xtandi .....	171
Xywav .....	210
Yervoy.....	143
Yondelis .....	110
Zaltrap .....	110
Zejula.....	171
Zelboraf.....	171
Zepzelca .....	110
Ziprasidone Mesylate .....	20
Zirabev.....	110
Zolinza .....	171
Zydelig .....	171
Zykadia.....	171
Zynlonta.....	110
Zyprexa Relprev .....	20

**Prior Authorization Group Description:**

Actimmune PA

**Drug Name(s)**

Actimmune

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. The requested dose is within the FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Alosetron PA

**Drug Name(s)**

Alosetron Hydrochloride

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindication(s) to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of irritable bowel syndrome with severe diarrhea (IBS-D) AND
2. Patient is female AND
3. Patient exhibits at least ONE of the following:
  - a. Frequent and severe abdominal pain/discomfort OR
  - b. Frequent bowel urgency or fecal incontinence OR
  - c. Disability or restriction of daily activities due to IBS AND
4. Prescriber has ruled out anatomic or biochemical abnormalities of the gastrointestinal tract

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Alpha-1-Proteinase Inhibitor PA - Prolastin-C

**Drug Name(s)**

Prolastin-C

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of alpha-1 antitrypsin deficiency (AATD) with clinically evident emphysema AND
2. Patient has a pre-treatment serum alpha-1 antitrypsin (AAT) level less than 11  $\mu\text{M/L}$  (80 mg/dL by immunodiffusion or 57 mg/dL using nephelometry) AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of alpha-1 antitrypsin deficiency (AATD) with clinically evident emphysema AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Anabolic Steroid PA – Danazol

**Drug Name(s)**

Danazol

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindication(s) to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has ONE of the following diagnoses:

A. Patient has an FDA labeled indication for the requested agent OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

2. ONE of the following:

A. Patient is NOT currently being treated with another androgen or anabolic steroid within the past 90 days OR

B. The current androgen or anabolic steroid will be discontinued prior to starting the requested agent OR

C. Prescriber has submitted documentation in support of therapy with more than one agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Anabolic Steroid PA – Oxandrolone

**Drug Name(s)**

Oxandrolone

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindication(s) to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has ONE of the following diagnoses:

A. Patient has AIDS/HIV-associated wasting syndrome AND BOTH of the following:

i. ONE of the following:

a. Unexplained involuntary weight loss (greater than 10% baseline body weight within 12 months, or 7.5% within 6 months) OR

b. Body mass index less than 20 kg/m<sup>2</sup> OR

c. At least 5% total body cell mass (BCM) loss within 6 months OR

d. In men: BCM less than 35% of total body weight and BMI less than 27 kg/m<sup>2</sup> OR

e. In women: BCM less than 23% of total body weight and BMI less than 27 kg/m<sup>2</sup> AND

ii. All other causes of weight loss have been ruled out OR

B. Patient is a female child or adolescent with Turner syndrome AND is currently receiving growth hormone OR

C. Patient has weight loss following extensive surgery, chronic infections, or severe trauma OR

D. Patient has chronic pain from osteoporosis OR

E. Patient is on long-term administration of oral or injectable corticosteroids AND

2. ONE of the following:

A. Patient is NOT currently being treated with another androgen or anabolic steroid within the past 90 days OR

B. The current androgen or anabolic steroid will be discontinued prior to starting the requested agent OR

C. Prescriber has submitted documentation in support of therapy with more than one agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Androgen Injectable PA - testosterone cypionate

**Drug Name(s)**

Testosterone Cypionate

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindication(s) to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has ONE of the following diagnoses:

A. Patient is a male with AIDS/HIV-associated wasting syndrome AND BOTH of the following:

i. ONE of the following:

a. Unexplained involuntary weight loss (greater than 10% baseline body weight within 12 months, or 7.5% within 6 months) OR

b. Body mass index less than 20 kg/m<sup>2</sup> OR

c. At least 5% total body cell mass (BCM) loss within 6 months OR

d. BCM less than 35% of total body weight and BMI less than 27 kg/m<sup>2</sup> AND

ii. All other causes of weight loss have been ruled out OR

B. Patient is a female with metastatic/inoperable breast cancer OR

C. Patient is a male with primary or secondary (hypogonadotropic) hypogonadism OR

D. Patient is an adolescent male with delayed puberty AND

2. If the patient is a male, ONE of the following:

A. Patient is not currently receiving testosterone replacement therapy AND has ONE of the following pretreatment levels:

i. Total serum testosterone level that is below the testing laboratory's lower limit of the normal range or is less than 300 ng/dL OR

ii. Free serum testosterone level that is below the testing laboratory's lower limit of the normal range OR

B. Patient is currently receiving testosterone replacement therapy AND has ONE of the following treated levels:

i. Total serum testosterone level that is within OR below the testing laboratory's lower limit of the normal range OR is less than 300 ng/dL OR

ii. Free serum testosterone level is within OR below the testing laboratory's normal range AND

3. ONE of the following:

A. Patient is NOT currently being treated with another androgen or anabolic steroid within the past 90 days OR

B. The current androgen or anabolic steroid will be discontinued prior to starting the requested agent OR

C. Prescriber has submitted documentation in support of therapy with more than one agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be 6 months for delayed puberty, 12 months for all other indications  
**Other Criteria:**



**Prior Authorization Group Description:**

Androgen Topical PA

**Drug Name(s)**

Androderm

Testosterone

Testosterone Pump

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindication(s) to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has ONE of the following diagnoses:

A. Patient has AIDS/HIV-associated wasting syndrome AND BOTH of the following:

i. ONE of the following:

a. Unexplained involuntary weight loss (greater than 10% baseline body weight within 12 months, or 7.5% within 6 months) OR

b. Body mass index less than 20 kg/m<sup>2</sup> OR

c. At least 5% total body cell mass (BCM) loss within 6 months OR

d. In men: BCM less than 35% of total body weight and BMI less than 27 kg/m<sup>2</sup> OR

e. In women: BCM less than 23% of total body weight and BMI less than 27 kg/m<sup>2</sup> AND

ii. All other causes of weight loss have been ruled out OR

B. Patient is a male with primary or secondary (hypogonadotropic) hypogonadism AND

2. If the patient is a male, ONE of the following:

A. Patient is not currently receiving testosterone replacement therapy AND has ONE of the following pretreatment levels:

i. Total serum testosterone level that is below the testing laboratory's lower limit of the normal range or is less than 300 ng/dL OR

ii. Free serum testosterone level that is below the testing laboratory's lower limit of the normal range OR

B. Patient is currently receiving testosterone replacement therapy AND has ONE of the following treated levels:

i. Total serum testosterone level that is within OR below the testing laboratory's lower limit of the normal range OR is less than 300 ng/dL OR

ii. Free serum testosterone level is within OR below the testing laboratory's normal range AND

3. ONE of the following:

A. Patient is NOT currently being treated with another androgen or anabolic steroid within the past 90 days OR

B. The current androgen or anabolic steroid will be discontinued prior to starting the requested agent OR

C. Prescriber has submitted documentation in support of therapy with more than one agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Antipsychotics PA

**Drug Name(s)**

Aripiprazole  
Aripiprazole Odt  
Asenapine Maleate Sl  
Caplyta  
Chlorpromazine Hcl  
Chlorpromazine Hydrochloride  
Clozapine  
Clozapine Odt  
Fanapt  
Fanapt Titration Pack  
Fluphenazine Decanoate  
Fluphenazine Hcl  
Fluphenazine Hydrochloride  
Haloperidol  
Haloperidol Decanoate  
Haloperidol Lactate  
Loxapine  
Lybalvi  
Molindone Hydrochloride  
Olanzapine  
Olanzapine Odt  
Paliperidone Er  
Perphenazine  
Quetiapine Fumarate  
Rexulti  
Risperidone  
Risperidone Odt  
Secuado  
Thioridazine Hcl  
Thiothixene  
Trifluoperazine Hcl  
Versacloz  
Ziprasidone Mesylate  
Zyprexa Relprevv

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that indicates the patient has been treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient has been treated with the requested agent OR
  - C. IF dementia-related psychosis and/or dementia related behavioral symptoms, BOTH of the following:
    1. Dementia-related psychosis is determined to be severe or the associated behavior puts the patient or others in danger AND
    2. Prescriber has documented that s/he has discussed the risk of increased mortality with the patient and/or the patient's surrogate decision maker

Approval authorizations will apply to the requested medication only.

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Apokyn PA

**Drug Name(s)**

Apokyn

Apomorphine

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

Patient will be using the requested agent in combination with a 5-HT3 antagonist (e.g., ondansetron, granisetron, dolasetron, palonosetron, alosetron)

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. The requested agent will be used to treat acute, intermittent hypomobility, “off” episodes (“end of dose wearing off” and unpredictable “on/off” episodes) associated with advanced Parkinson’s disease AND
2. The requested agent will be used in combination with agents used for therapy in Parkinson’s disease (e.g., levodopa, dopamine agonist, or monoamine oxidase B inhibitor)

**Age Restriction:**

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient’s diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient’s diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Arcalyst PA

**Drug Name(s)**

Arcalyst

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. ONE of the following:

A. Patient has been diagnosed with Cryopyrin-Associated Periodic Syndromes (CAPS) including Familial Cold Auto-inflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS) OR

B. BOTH of the following:

i. Patient has a diagnosis of deficiency of interleukin-1 receptor antagonist AND

ii. The requested agent is being used for maintenance of remission OR

C. BOTH of the following:

i. Patient has a diagnosis of recurrent pericarditis AND

ii. The requested agent is being used to reduce the risk of recurrence AND

2. Patient will NOT be using the requested agent in combination with another biologic agent

**Age Restriction:**

For diagnosis of CAPS including FCAS or MWS, patient is 12 years of age or over

For diagnosis of recurrent pericarditis and reduction in risk of recurrence, patient is 12 years of age or over

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Armodafinil PA

**Drug Name(s)**

Armodafinil

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. ONE of the following:

A. Patient has an FDA labeled indication for the requested agent OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

2. Patient will NOT be using the requested agent in combination with another target agent (i.e., modafinil)

**Age Restriction:**

Patient is 17 years of age or over

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Atopic Dermatitis PA – Pimecrolimus

**Drug Name(s)**

Pimecrolimus

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require ONE of the following:

1. Patient has a diagnosis of atopic dermatitis or vulvar lichen sclerosus AND ONE of the following:
  - a. Patient has had a trial and failure of a topical corticosteroid or topical corticosteroid combination preparation (e.g., hydrocortisone, triamcinolone) OR
  - b. Patient has a documented intolerance, FDA labeled contraindication or hypersensitivity to a topical corticosteroid or topical corticosteroid combination preparation OR
2. Patient has a diagnosis of facial seborrheic dermatitis associated with HIV infection AND BOTH of the following:
  - a. Patient is currently on an antiretroviral treatment regimen AND
  - b. ONE of the following:
    - i. Patient has had a trial and failure of a topical corticosteroid or topical antifungal treatment (e.g., hydrocortisone, triamcinolone, ketoconazole) OR
    - ii. Patient has a documented intolerance, FDA labeled contraindication or hypersensitivity to a topical corticosteroid or topical antifungal treatment OR
3. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Atopic Dermatitis PA – Tacrolimus

**Drug Name(s)**

Tacrolimus

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require ONE of the following:

1. Patient has a diagnosis of atopic dermatitis AND ONE of the following:
  - a. Patient has had a trial and failure with a topical corticosteroid or topical corticosteroid combination preparation (e.g., hydrocortisone, triamcinolone) OR
  - b. Patient has a documented intolerance, FDA labeled contraindication or hypersensitivity to a topical corticosteroid or topical corticosteroid combination preparation OR
2. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Benlysta IV PA

**Drug Name(s)**

Benlysta IV

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. ONE of the following:
  - a. Patient has a diagnosis of active systemic lupus erythematosus (SLE) disease AND the following:
    - i. Patient will continue standard SLE therapy [corticosteroids (e.g., methylprednisolone, prednisone), hydroxychloroquine, immunosuppressives (e.g., azathioprine, methotrexate, oral cyclophosphamide)] in combination with the requested agent OR
  - b. Patient has a diagnosis of active lupus nephritis (LN) AND the following:
    - i. Patient will continue standard LN therapy [corticosteroids (e.g., methylprednisolone, prednisone), immunosuppressives (e.g., azathioprine, mycophenolate)] in combination with the requested agent AND
2. Patient will NOT be using the requested agent in combination with another biologic agent AND
3. The requested dose is within the FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - a. Patient has diagnosis of active systemic lupus erythematosus (SLE) disease AND the following:
    - i. Patient will continue standard SLE therapy [corticosteroids (e.g., methylprednisolone, prednisone), hydroxychloroquine, immunosuppressives (e.g., azathioprine, methotrexate, oral cyclophosphamide)] in combination with the requested agent OR
  - b. Patient has a diagnosis of active lupus nephritis (LN) AND the following:
    - i. Patient will continue standard LN therapy [corticosteroids (e.g., methylprednisolone, prednisone), immunosuppressives (e.g., azathioprine, mycophenolate)] in combination with the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another biologic agent AND
5. The requested dose is within the FDA labeled dosing for the requested indication

**Age Restriction:**

For diagnosis of active systemic lupus erythematosus (SLE) disease, patient is 5 years of age or over. For diagnosis of active lupus nephritis (LN), patient is 18 years of age or over.

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Benlysta SC PA

**Drug Name(s)**

Benlysta SC

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. ONE of the following:
  - a. Patient has a diagnosis of active systemic lupus erythematosus (SLE) disease AND the following:
    - i. Patient will continue standard SLE therapy [corticosteroids (e.g., methylprednisolone, prednisone), hydroxychloroquine, immunosuppressives (e.g., azathioprine, methotrexate, oral cyclophosphamide)] in combination with the requested agent OR
  - b. Patient has a diagnosis of active lupus nephritis (LN) AND the following:
    - i. Patient will continue standard LN therapy [corticosteroids (e.g., methylprednisolone, prednisone), immunosuppressives (e.g., azathioprine, mycophenolate)] in combination with the requested agent AND
2. Patient will NOT be using the requested agent in combination with another biologic agent AND
3. The requested dose is within the FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - a. Patient has diagnosis of active systemic lupus erythematosus (SLE) disease AND the following:
    - i. Patient will continue standard SLE therapy [corticosteroids (e.g., methylprednisolone, prednisone), hydroxychloroquine, immunosuppressives (e.g., azathioprine, methotrexate, oral cyclophosphamide)] in combination with the requested agent OR
  - b. Patient has a diagnosis of active lupus nephritis (LN) AND the following:
    - i. Patient will continue standard LN therapy [corticosteroids (e.g., methylprednisolone, prednisone), immunosuppressives (e.g., azathioprine, mycophenolate)] in combination with the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another biologic agent AND
5. The requested dose is within the FDA labeled dosing for the requested indication

**Age Restriction:**

For diagnosis of active systemic lupus erythematosus (SLE) disease, patient is 18 years of age or over.

For diagnosis of active lupus nephritis (LN), patient is 18 years of age or over.

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Benzodiazepines PA – Clobazam

**Drug Name(s)**

Clobazam

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

a. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR

b. Prescriber states the patient has been treated with the requested agent AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. BOTH of the following:

i. Patient has ONE of the following diagnoses:

a. Seizure disorder OR

b. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Benzodiazepines PA – Clorazepate

**Drug Name(s)**

Clorazepate Dipotassium

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

a. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR

b. Prescriber states the patient has been treated with the requested agent AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. BOTH of the following:

i. Patient has ONE of the following diagnoses:

a. Seizure disorder OR

b. Anxiety disorder AND ONE of the following:

1) Patient has tried and has an inadequate response to a formulary selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) OR

2) Patient has an intolerance or hypersensitivity to a formulary SSRI or SNRI OR

3) Patient has an FDA labeled contraindication to a formulary SSRI or SNRI OR

c. Alcohol withdrawal OR

d. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Benzodiazepines PA – Diazepam

**Drug Name(s)**

Diazepam

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

a. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR

b. Prescriber states the patient has been treated with the requested agent AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. BOTH of the following:

i. Patient has ONE of the following diagnoses:

a. Seizure disorder OR

b. Anxiety disorder AND ONE of the following:

1) Patient has tried and had an inadequate response to a formulary selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) OR

2) Patient has an intolerance or hypersensitivity to a formulary SSRI or SNRI OR

3) Patient has an FDA labeled contraindication to a formulary SSRI or SNRI OR

c. Skeletal muscle spasms OR

d. Alcohol withdrawal OR

e. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Benzodiazepines PA – Lorazepam

**Drug Name(s)**

Lorazepam

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

a. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR

b. Prescriber states the patient has been treated with the requested agent AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. BOTH of the following:

i. Patient has ONE of the following diagnoses:

a. Anxiety disorder AND ONE of the following:

1) Patient has tried and had an inadequate response to a formulary selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) OR

2) Patient has an intolerance or hypersensitivity to a formulary SSRI or SNRI OR

3) Patient has an FDA labeled contraindication to a formulary SSRI or SNRI OR

b. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Benzodiazepines PA – Sympazan

**Drug Name(s)**

Sympazan

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

a. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR

b. Prescriber states the patient has been treated with the requested agent AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. BOTH of the following:

i. Patient has ONE of the following diagnoses:

a. Seizure disorder OR

b. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Cosentyx

**Drug Name(s)**

Cosentyx

Cosentyx Sensoready Pen

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient has been treated with the requested agent AND is at risk if therapy is changed OR
  - C. Patient’s medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
  - D. Patient’s diagnosis does NOT require a conventional prerequisite agent OR
  - E. Patient’s medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
  - F. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
  - G. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan’s Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE conventional prerequisite agent is required for diagnoses of psoriatic arthritis or plaque psoriasis

NO prerequisites are required for diagnoses of ankylosing spondylitis, enthesitis related arthritis, or non-radiographic axial spondyloarthritis

Formulary conventional agents for psoriatic arthritis include cyclosporine, leflunomide, methotrexate, or sulfasalazine

Formulary conventional topical or systemic antipsoriatic agents include acitretin, calcipotriene, methotrexate, tazarotene, or topical corticosteroids

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Enbrel

**Drug Name(s)**

Enbrel

Enbrel Mini

Enbrel Sureclick

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient has been treated with the requested agent AND is at risk if therapy is changed OR
  - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
  - D. Patient's diagnosis does NOT require a conventional prerequisite agent OR
  - E. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
  - F. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
  - G. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE conventional prerequisite agent is required for diagnoses of psoriatic arthritis, plaque psoriasis, rheumatoid arthritis, or juvenile idiopathic arthritis

NO prerequisites are required for a diagnosis of ankylosing spondylitis

Formulary conventional agents for rheumatoid arthritis, juvenile idiopathic arthritis, or psoriatic arthritis include methotrexate, sulfasalazine, or leflunomide

Formulary conventional topical or systemic antipsoriatic agents include acitretin, calcipotriene, methotrexate, tazarotene, or topical corticosteroids

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Humira

**Drug Name(s)**

Humira

Humira Pediatric Crohns Disease Starter Pack

Humira Pen

Humira Pen-Cd/Uc/Hs Starter

Humira Pen-Pediatric Uc Starter Pack

Humira Pen-Ps/Uv Starter

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient has been treated with the requested agent AND is at risk if therapy is changed OR
  - C. Patient’s medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
  - D. Patient’s diagnosis does NOT require a conventional prerequisite agent OR
  - E. Patient’s medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
  - F. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
  - G. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan’s Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be 12 weeks for initial use for ulcerative colitis, 12 months for all others

**Other Criteria:**

Use of ONE conventional prerequisite agent is required for diagnoses of psoriatic arthritis, plaque psoriasis, rheumatoid arthritis, juvenile idiopathic arthritis, Crohn's disease, or ulcerative colitis

NO prerequisites are required for diagnoses of ankylosing spondylitis, hidradenitis suppurativa, or uveitis

Formulary conventional agents for rheumatoid arthritis, juvenile idiopathic arthritis, or psoriatic arthritis include methotrexate, sulfasalazine, or leflunomide

Formulary conventional topical or systemic antipsoriatic agents include acitretin, calcipotriene, methotrexate, tazarotene, or topical corticosteroids

Formulary conventional agents for crohn's disease include methotrexate, sulfasalazine, corticosteroids, azathioprine, or mercaptopurine

Formulary conventional agents for ulcerative colitis include 5-aminosalicylates, corticosteroids, azathioprine, or mercaptopurine

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Renflexis

**Drug Name(s)**

Renflexis

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient has been treated with the requested agent AND is at risk if therapy is changed OR
  - C. ONE of the following:
    - i. Patient’s diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
      - a. Patient’s medication history indicates use of preferred biologic immunomodulator agent(s) OR
      - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
      - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
    - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan’s Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of TWO preferred agents (Enbrel, Humira, Rinvoq, Xeljanz, or Xeljanz XR) is required for diagnosis of rheumatoid arthritis



Use of TWO preferred agents (Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Xeljanz, or Xeljanz XR) is required for diagnosis of psoriatic arthritis

Use of TWO preferred agents (Cosentyx, Enbrel, Humira, Skyrizi, or Stelara) is required for diagnosis of plaque psoriasis

Use of TWO preferred agents (Cosentyx, Enbrel, Humira, Rinvoq, Xeljanz, or Xeljanz XR) is required for diagnosis of ankylosing spondylitis

Use of TWO preferred agents (Humira, Skyrizi, and Stelara) is required for diagnosis of adult Crohn's disease

Use of TWO preferred agents (Humira, Rinvoq, Stelara, Xeljanz, or Xeljanz XR) is required for diagnosis of adult ulcerative colitis

Only the preferred agent Humira is required for diagnoses of pediatric Crohn's disease or pediatric ulcerative colitis

NO preferred agent is required for diagnosis of adult fistulizing Crohn's disease

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Riabni

**Drug Name(s)**

Riabni

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for initial approval require ONE of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND ONE of the following:

A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR

B. Prescriber states the patient has been treated with the requested agent OR

2. ALL of the following:

A. ONE of the following:

i. Patient has a diagnosis of rheumatoid arthritis AND ONE of the following:

a. Patient’s medication history indicates use of preferred biologic immunomodulator agent(s) OR

b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR

c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR

ii. Patient has another FDA labeled indication or an indication that is supported in CMS approved compendia AND

B. Patient has been screened for hepatitis B infection measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) and has begun therapy, if appropriate, prior to receiving the requested agent AND

C. Patient will NOT be using the requested agent in combination with another biologic immunomodulator AND

D. Patient does NOT have any FDA labeled limitation(s) of use for the requested agent that is not otherwise supported in NCCN guidelines

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan’s Prior Authorization criteria AND

2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND

3. ONE of the following:

A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR

B. Prescriber states the patient has been treated with the requested agent OR

C. ALL of the following:

- i. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- ii. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
- iii. Patient will NOT be using the requested agent in combination with another biologic immunomodulator AND
- iv. Patient does NOT have any FDA labeled limitation(s) of use for the requested agent that is not otherwise supported in NCCN guidelines

Use of TWO preferred agents (Enbrel, Humira, Rinvoq, Xeljanz, or Xeljanz XR) is required for diagnosis of rheumatoid arthritis

ALL other diagnoses do NOT require any preferred agents

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Rinvoq

**Drug Name(s)**

Rinvoq

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient has been treated with the requested agent AND is at risk if therapy is changed OR
  - C. Patient’s medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
  - D. ONE of the following:
    - i. Patient has an FDA labeled indication other than moderate to severe atopic dermatitis for the requested agent AND ONE of the following:
      - a. Patient’s diagnosis does NOT require a conventional prerequisite agent OR
      - b. Patient’s medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
      - c. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
      - d. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication OR
    - ii. Patient has a diagnosis of moderate to severe atopic dermatitis AND ONE of the following:
      - a. Patient’s medication history indicates use of TWO conventional prerequisite agents (i.e., ONE formulary topical corticosteroid AND ONE formulary topical calcineurin inhibitor) for the requested indication OR
      - b. Patient has an intolerance or hypersensitivity to TWO conventional prerequisite agents (i.e., ONE formulary topical corticosteroid AND ONE formulary topical calcineurin inhibitor) for the requested indication OR
      - c. Patient has an FDA labeled contraindication to TWO conventional prerequisite agents (i.e., ONE formulary topical corticosteroid AND ONE formulary topical calcineurin inhibitor) for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Use of ONE conventional prerequisite agent is required for diagnoses of rheumatoid arthritis, psoriatic arthritis, or ulcerative colitis

Use of TWO conventional prerequisite agents (i.e., ONE formulary topical corticosteroid AND ONE formulary topical calcineurin inhibitor) are required for diagnosis of moderate to severe atopic dermatitis

NO prerequisites are required for a diagnosis of ankylosing spondylitis

Formulary conventional agents for rheumatoid arthritis include methotrexate, hydroxychloroquine, sulfasalazine, or leflunomide

Formulary conventional agents for psoriatic arthritis include methotrexate, sulfasalazine, or leflunomide

Formulary conventional agents for ulcerative colitis include 5-aminosalicylates, corticosteroids, azathioprine, mercaptopurine

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Rituxan

**Drug Name(s)**

Rituxan

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for initial approval require ONE of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND ONE of the following:

A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR

B. Prescriber states the patient has been treated with the requested agent OR

2. ALL of the following:

A. ONE of the following:

i. Patient has a diagnosis of rheumatoid arthritis AND ONE of the following:

a. Patient’s medication history indicates use of preferred biologic immunomodulator agent(s) OR

b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR

c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR

ii. Patient has another FDA labeled indication or an indication that is supported in CMS approved compendia AND

B. Patient has been screened for hepatitis B infection measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) and has begun therapy, if appropriate, prior to receiving the requested agent AND

C. Patient will NOT be using the requested agent in combination with another biologic immunomodulator AND

D. Patient does NOT have any FDA labeled limitation(s) of use for the requested agent that is not otherwise supported in NCCN guidelines

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan’s Prior Authorization criteria AND

2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND

3. ONE of the following:

A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR

B. Prescriber states the patient has been treated with the requested agent OR

C. ALL of the following:

- i. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- ii. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
- iii. Patient will NOT be using the requested agent in combination with another biologic immunomodulator AND
- iv. Patient does NOT have any FDA labeled limitation(s) of use for the requested agent that is not otherwise supported in NCCN guidelines

Use of TWO preferred agents (Enbrel, Humira, Rinvoq, Xeljanz, or Xeljanz XR) is required for diagnosis of rheumatoid arthritis

ALL other diagnoses do NOT require any preferred agents

**Prior Authorization Group Description:**

Biologic Immunomodulators PA - Rituxan Hycela

**Drug Name(s)**

Rituxan Hycela

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient has been treated with the requested agent OR
  - C. ALL of the following:
    - i. Patient has been screened for hepatitis B infection measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) and has begun therapy, if appropriate, prior to receiving the requested agent AND
    - ii. Patient will NOT be using the requested agent in combination with another biologic immunomodulator AND
    - iii. Patient does NOT have any FDA labeled limitation(s) of use for the requested agent that is not otherwise supported in NCCN guidelines

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
3. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient has been treated with the requested agent OR
  - C. ALL of the following:
    - i. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
    - ii. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND



- iii. Patient will NOT be using the requested agent in combination with another biologic immunomodulator AND
- iv. Patient does NOT have any FDA labeled limitation(s) of use for the requested agent that is not otherwise supported in NCCN guidelines

There are no preferred agents required for Rituxan Hycela

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Ruxience

**Drug Name(s)**

Ruxience

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ONE of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND ONE of the following:

A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR

B. Prescriber states the patient has been treated with the requested agent OR

2. ALL of the following:

A. ONE of the following:

i. Patient has a diagnosis of rheumatoid arthritis AND ONE of the following:

a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR

b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR

c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR

ii. Patient has another FDA labeled indication or an indication that is supported in CMS approved compendia AND

B. Patient has been screened for hepatitis B infection measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) and has begun therapy, if appropriate, prior to receiving the requested agent AND

C. Patient will NOT be using the requested agent in combination with another biologic immunomodulator AND

D. Patient does NOT have any FDA labeled limitation(s) of use for the requested agent that is not otherwise supported in NCCN guidelines

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND

3. ONE of the following:

A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR

B. Prescriber states the patient has been treated with the requested agent OR

C. ALL of the following:

- i. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- ii. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
- iii. Patient will NOT be using the requested agent in combination with another biologic immunomodulator AND
- iv. Patient does NOT have any FDA labeled limitation(s) of use for the requested agent that is not otherwise supported in NCCN guidelines

Use of TWO preferred agents (Enbrel, Humira, Rinvoq, Xeljanz, or Xeljanz XR) is required for diagnosis of rheumatoid arthritis

ALL other diagnoses do NOT require any preferred agents

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Skyrizi

**Drug Name(s)**

Skyrizi

Skyrizi Pen

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient has been treated with the requested agent AND is at risk if therapy is changed OR
  - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
  - D. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
  - E. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
  - F. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE conventional prerequisite agent is required for diagnoses of Crohn's disease, plaque psoriasis, or psoriatic arthritis

Formulary conventional agents for crohn's disease include methotrexate, sulfasalazine, corticosteroids, azathioprine, or mercaptopurine

Formulary conventional topical or systemic antipsoriatic agents include acitretin, calcipotriene, methotrexate, tazarotene, or topical corticosteroids

Formulary conventional agents for psoriatic arthritis include methotrexate, sulfasalazine, or leflunomide

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Stelara

**Drug Name(s)**

Stelara

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient has been treated with the requested agent AND is at risk if therapy is changed OR
  - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
  - D. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
  - E. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
  - F. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE conventional prerequisite agent is required for diagnoses of psoriatic arthritis, plaque psoriasis, ulcerative colitis, or Crohn's disease

Formulary conventional agents for psoriatic arthritis include cyclosporine, leflunomide, methotrexate, or sulfasalazine

Formulary conventional topical or systemic antipsoriatic agents include acitretin, calcipotriene, methotrexate, tazarotene, or topical corticosteroids

Formulary conventional agents for Crohn's disease include methotrexate, sulfasalazine, corticosteroids, azathioprine, mercaptopurine

Formulary conventional agents for ulcerative colitis include 5-aminosalicylates, corticosteroids, azathioprine, mercaptopurine

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Truxima

**Drug Name(s)**

Truxima

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for initial approval require ONE of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND ONE of the following:

A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR

B. Prescriber states the patient has been treated with the requested agent OR

2. ALL of the following:

A. ONE of the following:

i. Patient has a diagnosis of rheumatoid arthritis AND ONE of the following:

a. Patient’s medication history indicates use of preferred biologic immunomodulator agent(s) OR

b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR

c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR

ii. Patient has another FDA labeled indication or an indication that is supported in CMS approved compendia AND

B. Patient has been screened for hepatitis B infection measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) and has begun therapy, if appropriate, prior to receiving the requested agent AND

C. Patient will NOT be using the requested agent in combination with another biologic immunomodulator AND

D. Patient does NOT have any FDA labeled limitation(s) of use for the requested agent that is not otherwise supported in NCCN guidelines

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan’s Prior Authorization criteria AND

2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND

3. ONE of the following:

A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR

B. Prescriber states the patient has been treated with the requested agent OR



C. ALL of the following:

- i. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- ii. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
- iii. Patient will NOT be using the requested agent in combination with another biologic immunomodulator AND
- iv. Patient does NOT have any FDA labeled limitation(s) of use for the requested agent that is not otherwise supported in NCCN guidelines

Use of TWO preferred agents (Enbrel, Humira, Rinvoq, Xeljanz, or Xeljanz XR) is required for diagnosis of rheumatoid arthritis

ALL other diagnoses do NOT require any preferred agents

**Prior Authorization Group Description:**

Biologic Immunomodulators PA - Xeljanz Solution

**Drug Name(s)**

Xeljanz Solution

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient has been treated with the requested agent AND is at risk if therapy is changed OR
  - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
  - D. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
  - E. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
  - F. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE conventional prerequisite agent is required for diagnosis of juvenile idiopathic arthritis

Formulary conventional agents for juvenile idiopathic arthritis include leflunomide, methotrexate, or sulfasalazine

**Prior Authorization Group Description:**

Biologic Immunomodulators PA - Xeljanz Tablet

**Drug Name(s)**

Xeljanz Tablet

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient has been treated with the requested agent AND is at risk if therapy is changed OR
  - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
  - D. Patient's diagnosis does NOT require a conventional prerequisite agent OR
  - E. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
  - F. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
  - G. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE conventional prerequisite agent is required for diagnoses of psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, or ulcerative colitis

NO prerequisites are required for diagnosis of ankylosing spondylitis

Formulary conventional agents for juvenile idiopathic arthritis, psoriatic arthritis, or rheumatoid arthritis include methotrexate, sulfasalazine, or leflunomide

Formulary conventional agents for ulcerative colitis include 5-aminosalicylates, corticosteroids, azathioprine, mercaptopurine

**Prior Authorization Group Description:**

Biologic Immunomodulators PA - Xeljanz XR

**Drug Name(s)**

Xeljanz Xr

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient has been treated with the requested agent AND is at risk if therapy is changed OR
  - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
  - D. Patient's diagnosis does NOT require a conventional prerequisite agent OR
  - E. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
  - F. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
  - G. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE conventional prerequisite agent is required for diagnoses of psoriatic arthritis, rheumatoid arthritis, or ulcerative colitis

NO prerequisites are required for diagnosis of ankylosing spondylitis

Formulary conventional agents for psoriatic arthritis or rheumatoid arthritis include methotrexate, sulfasalazine, or leflunomide

Formulary conventional agents for ulcerative colitis include 5-aminosalicylates, corticosteroids, azathioprine, mercaptopurine

**Prior Authorization Group Description:**

Carbaglu PA

**Drug Name(s)**

Carglumic

**Indications:**

All FDA-Approved Indications, Some Medically-Accepted Indications.

**Off-Label Uses:**

Acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA)

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of ONE of the following:
  - a. Acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS) OR
  - b. Chronic hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS) OR
  - c. Acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA) AND
2. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:**

**Prescriber Restrictions:** Prescriber is a specialist in the area of the patient's diagnosis (e.g., geneticist, nephrologist, metabolic disorders) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Chenodal PA

**Drug Name(s)**

Chenodal

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of radiolucent stones in a well-opacifying gallbladder AND
2. The requested dose is within the FDA labeled dosing for the requested indication

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Chorionic Gonadotropin PA

**Drug Name(s)**

Chorionic Gonadotropin

Pregnyl W/Diluent Benzyl Alcohol/Nacl

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

Requested agent will be used to promote fertility AND Requested agent will be used to treat erectile dysfunction AND FDA labeled contraindication(s) to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of prepubertal cryptorchidism not due to anatomic obstruction OR

B. Patient is a male with a diagnosis of hypogonadotropic hypogonadism (hypogonadism secondary to pituitary deficiency) AND BOTH of the following:

i. Patient has a measured current or pretreatment total serum testosterone level that is below the testing laboratory's lower limit of the normal range or is less than 300 ng/dL OR a free serum

testosterone level that is below the testing laboratory's lower limit of the normal range AND

ii. Patient has measured luteinizing hormone (LH) AND follicle-stimulating hormone (FSH) levels that are at (low-normal) or below the testing laboratory's normal range OR

C. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Cinacalcet PA

**Drug Name(s)**

Cinacalcet Hydrochloride

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindication(s) to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has ONE of the following:

A. An FDA approved indication or an indication that is supported in CMS approved compendia for the requested agent not otherwise excluded from Part D [i.e., secondary hyperparathyroidism due to end-stage renal disease (ESRD) on dialysis] AND ONE of the following:

i. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR

ii. Prescriber states the patient is currently being treated with the requested agent AND is at risk if therapy is changed OR

B. A diagnosis of hypercalcemia due to parathyroid carcinoma OR

C. A diagnosis of primary hyperparathyroidism (HPT) AND BOTH of the following:

i. Patient has a pretreatment serum calcium level that is above the testing laboratory's upper limit of normal AND

ii. Patient is unable to undergo parathyroidectomy OR

D. Another indication that is supported in CMS approved compendia for the requested agent not otherwise excluded from Part D

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Colony Stimulating Factors PA – Granix

**Drug Name(s)**

Granix

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:**

**Prescriber Restrictions:** Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, hematologist, infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 6 months

**Other Criteria:**

**Prior Authorization Group Description:**

Corlanor PA

**Drug Name(s)**

Corlanor

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindication(s) to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has stable, symptomatic chronic heart failure (e.g., NYHA Class II, III, IV: ACCF/AHA Class C, D)

AND

2. ONE of following:

a. ALL of the following:

i. The requested agent is for a pediatric patient, 6 months or over AND

ii. Patient has heart failure due to dilated cardiomyopathy (DCM) AND

iii. Patient is in sinus rhythm with an elevated heart rate OR

b. ALL of the following:

i. The requested agent is for an adult patient AND

ii. Patient has a baseline OR current left ventricular ejection fraction of 35% or less AND

iii. Patient is in sinus rhythm with a resting heart rate of 70 beats or greater per minute prior to initiating therapy with the requested agent AND

iv. ONE of the following:

1. Patient is on a maximally tolerated dose of beta blocker (e.g., bisoprolol, carvedilol, metoprolol) OR

2. Patient has a documented intolerance, FDA labeled contraindication(s), or hypersensitivity to a beta blocker

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Cresemba PA

**Drug Name(s)**

Cresemba

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindication(s) to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of invasive aspergillosis OR

B. Patient has a diagnosis of invasive mucormycosis OR

C. Patient has another indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require BOTH of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following

A. Patient has a diagnosis of invasive aspergillosis and patient has continued indicators of active disease (e.g., continued radiologic findings, direct microscopy findings, histopathology findings, positive cultures, positive serum galactomannan assay) OR

B. Patient has a diagnosis of invasive mucormycosis and patient has continued indicators of active disease (e.g., continued radiologic findings, direct microscopy findings, histopathology findings, positive cultures, positive serum galactomannan assay) OR

C. BOTH of the following:

i. Patient has another indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient has shown clinical benefit with the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 6 months

**Other Criteria:**

**Prior Authorization Group Description:**

Crysvita PA

**Drug Name(s)**

Crysvita

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. BOTH of the following:

i. Patient has a diagnosis of X-linked hypophosphatemia (XLH) as confirmed by ONE of the following:

a. Genetic testing OR

b. Elevated levels of intact fibroblast growth factor 23 (FGF23) OR

c. Prescriber has provided information indicating the patient has a positive family history of XLH AND

ii. ONE of the following:

a. Patient's epiphyseal plate has not fused OR

b. Patient's epiphyseal plate has fused AND the patient is experiencing symptoms of XLH (e.g., bone pain, fractures, limited mobility) OR

B. Patient has a diagnosis of tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors AND BOTH of the following:

i. The requested agent is being used to treat FGF23 related hypophosphatemia AND

ii. The tumor cannot be curatively surgically resected or localized AND

2. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of X-linked hypophosphatemia (XLH) OR

B. Patient has a diagnosis of tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors AND

3. Patient has had clinical benefit with the requested agent (e.g., enhanced height velocity, improvement in lower extremity bowing and associated abnormalities, radiographic evidence of epiphyseal healing, improvement in bone pain, enhanced mobility, improvement in osteomalacia, improvement in fracture healing) AND

4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:**

For diagnosis of X-linked hypophosphatemia (XLH), patient is 6 months of age or over. For diagnosis of tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors, patient is 2 years of age or over.

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., nephrologist, endocrinologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Cystadrops PA

**Drug Name(s)**

Cystadrops

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., ophthalmologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Cystaran PA

**Drug Name(s)**

Cystaran

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., ophthalmologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Cystinosis Agents PA – Cystagon

**Drug Name(s)**

Cystagon

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindication(s) to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of nephropathic cystinosis AND
2. Prescriber has performed a baseline white blood cell (WBC) cystine level test AND
3. The requested dose is within the FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of nephropathic cystinosis AND
3. Patient has shown clinical improvement (e.g., decrease in WBC cystine levels from baseline) with the requested agent AND
4. The requested dose is within the FDA labeled dosing for the requested indication

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Dalfampridine PA

**Drug Name(s)**

Dalfampridine Er

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of multiple sclerosis (MS) AND
2. ONE of the following:
  - A. If indicated, the requested agent will be used in combination with a disease modifying agent [e.g., Aubagio, Avonex, Bafiertam, Betaseron, dimethyl fumarate (e.g., Tecfidera), Extavia, Gilenya, glatiramer (e.g., Copaxone, Glatopa), Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, Vumerity, Zeposia] OR
  - B. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to a disease modifying agent

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of multiple sclerosis (MS) AND
3. ONE of the following:
  - A. If indicated, the requested agent will be used in combination with a disease modifying agent [e.g., Aubagio, Avonex, Bafiertam, Betaseron, dimethyl fumarate (e.g., Tecfidera), Extavia, Gilenya, glatiramer (e.g., Copaxone, Glatopa), Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, Vumerity, Zeposia] OR
  - B. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to a disease modifying agent AND
4. Patient has demonstrated a stabilization or improvement from baseline in timed walking speed (timed 25-foot walk)

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Initial approval will be for 3 months, renewal approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Droxidopa PA

**Drug Name(s)**

Droxidopa

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of neurogenic orthostatic hypotension (nOH) AND
2. Prescriber has performed baseline blood pressure readings while the patient is sitting or supine (lying face up), AND also within 3 minutes of standing from a supine position AND
3. Patient has a decrease of at least 20 mmHg in systolic blood pressure or 10 mmHg diastolic blood pressure within three minutes after standing AND
4. Patient has persistent and consistent symptoms of neurogenic orthostatic hypotension (nOH) caused by ONE of the following:
  - A. Primary autonomic failure [Parkinson's disease (PD), multiple system atrophy, or pure autonomic failure] OR
  - B. Dopamine beta-hydroxylase deficiency OR
  - C. Non-diabetic autonomic neuropathy AND
5. Prescriber has assessed the severity of the patient's baseline symptoms of dizziness, lightheadedness, feeling faint, or feeling like the patient may black out AND
6. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of neurogenic orthostatic hypotension (nOH) AND
3. Patient has had improvements or stabilization with the requested agent as indicated by improvement in severity from baseline symptoms of ONE of the following:
  - A. Dizziness
  - B. Lightheadedness
  - C. Feeling faint
  - D. Feeling like the patient may black out AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cardiologist, neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be 1 month for initial, 3 months for renewal

**Other Criteria:**

**Prior Authorization Group Description:**

Dupixent PA

**Drug Name(s)**

Dupixent

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for initial approval require BOTH of:

1. ONE of:

A. Patient (pt) has a diagnosis of moderate-to-severe atopic dermatitis AND BOTH of:

i. ONE of:

a. Pt has tried and failed a topical steroid (e.g., triamcinolone) OR

b. Pt has an intolerance or hypersensitivity to a topical steroid OR

c. Pt has an FDA labeled contraindication to a topical steroid AND

ii. ONE of:

a. Pt has tried and failed a topical calcineurin inhibitor (e.g., pimecrolimus, tacrolimus) OR

b. Pt has an intolerance or hypersensitivity to a topical calcineurin inhibitor OR

c. Pt has an FDA labeled contraindication to a topical calcineurin inhibitor OR

B. Pt has a diagnosis of moderate-to-severe asthma AND ALL of:

i. Pt has ONE of:

a. Frequent severe asthma exacerbations requiring two or more courses of systemic corticosteroids (steroid burst) within the past 12 months OR

b. Serious asthma exacerbations requiring hospitalization, mechanical ventilation, or visit to the emergency room or urgent care within the past 12 months OR

c. Controlled asthma that worsens when the doses of inhaled or systemic corticosteroids are tapered OR

d. Pt has a baseline Forced Expiratory Volume (FEV1) that is less than 80% of predicted AND

ii. ONE of:

a. Pt is NOT currently being treated with the requested agent AND is currently being treated with a maximally tolerated inhaled corticosteroid (ICS) OR

b. Pt is currently being treated with the requested agent AND ONE of:

1. Pt is currently being treated with an ICS that is adequately dosed to control symptoms OR

2. Pt is currently being treated with a maximally tolerated ICS OR

3. Pt has an intolerance or hypersensitivity to an ICS OR

4. Pt has FDA labeled contraindication to an ICS AND

iii. ONE of:

a. Pt is currently being treated with ONE of:

1. A long-acting beta-2 agonist (LABA) OR

2. A leukotriene receptor antagonist (LRTA) OR

3. A long-acting muscarinic antagonist (LAMA) OR

4. Theophylline OR

Initial criteria continues: see Other Criteria

**Age Restriction:**

For diagnosis of moderate-to-severe atopic dermatitis, patient is 6 years of age or over. For diagnosis of moderate-to-severe asthma, patient is 6 years of age or over. For diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP), patient is 18 years of age or over.

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, dermatologist, immunologist, otolaryngologist, pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- b. Pt has an intolerance or hypersensitivity to a LABA, LRTA, LAMA, or theophylline OR
- c. Pt has an FDA labeled contraindication to a LABA, LRTA, LAMA, or theophylline AND
- iv. Pt will continue asthma control therapy (e.g., ICS, LABA, LRTA, LAMA, theophylline) in combination with the requested agent AND
- v. Pt will NOT be using the requested agent in combination with Xolair or with an injectable interleukin 5 (IL-5) inhibitor (e.g., Cinqair, Fasenra, Nucala) for the requested indication OR
- C. Pt has a diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) AND ALL of:
  - a. ONE of:
    - 1. Pt has tried and had an inadequate response to an oral systemic corticosteroid OR
    - 2. Pt has an intolerance or hypersensitivity to an oral systemic corticosteroid OR
    - 3. Pt has an FDA labeled contraindication to an oral systemic corticosteroid AND
  - b. ONE of:
    - 1. Pt has tried and had an inadequate response to an intranasal corticosteroid (e.g., fluticasone) OR
    - 2. Pt has an intolerance or hypersensitivity to an intranasal corticosteroid OR
    - 3. Pt has an FDA labeled contraindication to an intranasal corticosteroid AND
  - c. Pt will continue standard maintenance therapy (e.g., intranasal corticosteroids) in combination with the requested agent AND
- 2. The requested dose is within the FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of:

- 1. Pt has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. ONE of:
  - A. Pt has a diagnosis of moderate-to-severe atopic dermatitis OR
  - B. Pt has a diagnosis of moderate-to-severe asthma AND ALL of:
    - i. ONE of:
      - a. Pt is currently being treated with standard therapy [e.g., ICS, long-acting beta-2 agonist (LABA), leukotriene receptor antagonist (LRTA), long-acting muscarinic antagonist (LAMA), theophylline] OR
      - b. Pt has an intolerance or hypersensitivity to a standard therapy OR
      - c. Patient has an FDA labeled contraindication to a standard therapy AND
    - ii. Patient will continue asthma control therapy (e.g., ICS, LABA, LTRA, LAMA, theophylline) in combination with the requested agent AND

- iii. Pt will NOT be using the requested agent in combination with Xolair or with an injectable interleukin 5 (IL-5) inhibitor (e.g., Cinqair, Fasenra, Nucala) for the requested indication OR
- C. Pt has a diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) AND the following:
  - i. Pt will continue standard maintenance therapy (e.g., intranasal corticosteroids) in combination with the requested agent AND
  - 3. Patient has had clinical benefit with the requested agent AND
  - 4. The requested dose is within the FDA labeled dosing for the requested indication



**Prior Authorization Group Description:**

Emgality PA

**Drug Name(s)**

Emgality

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. Patient has a diagnosis of migraine AND BOTH of the following:

i. Patient has 4 migraine headaches or more per month AND

ii. ONE of the following:

a. Patient has tried and had an inadequate response to a conventional migraine prophylaxis agent [e.g., beta blockers (propranolol), anticonvulsants (divalproex, topiramate)] OR

b. Patient has an intolerance, or hypersensitivity to a conventional migraine prophylaxis agent OR

c. Patient has an FDA labeled contraindication to a conventional migraine prophylaxis agent OR

B. Patient has a diagnosis of episodic cluster headache AND BOTH of the following:

i. Patient has had at least 5 cluster headache attacks AND

ii. Patient has had at least two cluster periods lasting 7 days to one year and separated by pain-free remission periods of 3 months or more AND

2. Patient will NOT be using the requested agent in combination with another calcitonin gene-related peptide (CGRP) agent for migraine prophylaxis

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of migraine OR

B. Patient has a diagnosis of episodic cluster headache AND

3. Patient has had clinical benefit with the requested agent AND

4. Patient will NOT be using the requested agent in combination with another calcitonin gene-related peptide (CGRP) agent for migraine prophylaxis

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Epclusa PA

**Drug Name(s)**

Epclusa

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. ONE of the following:

A. Patient has a diagnosis of hepatitis C confirmed by serological markers OR

B. Patient is a hepatitis C virus (HCV) - uninfected solid organ transplant recipient AND BOTH of the following:

i. Patient received an HCV - viremic donor organ AND

ii. The requested agent is being used for prophylaxis AND

2. Prescriber has screened the patient for current or prior hepatitis B viral (HBV) infection and if positive, will monitor the patient for HBV flare-up or reactivation during and after treatment with the requested agent AND

3. The requested agent will be used in a treatment regimen and length of therapy that is supported in FDA approved labeling or AASLD/IDSA guidelines for the patient's diagnosis and genotype AND

4. The dosing of the requested agent is within the FDA labeled dosing or supported in AASLD/IDSA guideline dosing for the requested indication

**Age Restriction:**

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, hepatologist or infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Duration of therapy: Based on FDA approved labeling or AASLD/IDSA guideline supported

**Other Criteria:**

**Prior Authorization Group Description:**

Epidiolex PA

**Drug Name(s)**

Epidiolex

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. ONE of the following:

A. Patient has a diagnosis of seizures associated with Lennox-Gastaut syndrome OR

B. Patient has a diagnosis of seizures associated with Dravet syndrome OR

C. Patient has a diagnosis of seizures associated with tuberous sclerosis complex AND

2. The requested dose is within the FDA labeled dosing for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Erythropoietin Stimulating Agents PA – Retacrit

**Drug Name(s)**

Retacrit

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. The requested agent is being prescribed for ONE of the following:

A. To reduce the possibility of allogeneic blood transfusion in a surgery patient AND the patient's hemoglobin level is greater than 10 g/dL but 13 g/dL or less OR

B. Anemia due to myelosuppressive chemotherapy for a non-myeloid malignancy AND ALL of the following:

i. Patient's hemoglobin level is less than 10 g/dL for patients initiating ESA therapy OR less than 12 g/dL for patients stabilized on therapy (measured within the previous 4 weeks) AND

ii. Patient is being concurrently treated with chemotherapy with or without radiation (treatment period extends to 8 weeks post chemotherapy) AND

iii. The intent of chemotherapy is non-curative OR

C. Anemia associated with chronic kidney disease in a patient NOT on dialysis AND ALL of the following:

i. Patient's hemoglobin level is less than 10 g/dL for patients initiating ESA therapy OR 11 g/dL or less for patients stabilized on therapy (measured within the previous 4 weeks) AND

ii. The rate of hemoglobin decline indicates the likelihood of requiring a RBC transfusion AND

iii. The intent of therapy is to reduce the risk of alloimmunization and/or other RBC transfusion related risks OR

D. Anemia resulting from zidovudine treatment of HIV infection AND the patient's hemoglobin level is less than 12 g/dL for patients initiating ESA therapy OR less than or equal to 12 g/dL for patients stabilized on therapy (measured within the previous 4 weeks) OR

E. Another indication that is supported in CMS approved compendia for the requested agent AND the patient's hemoglobin level is less than 12 g/dL for patients initiating ESA therapy OR less than or equal to 12 g/dL for patients stabilized on therapy (measured within the previous 4 weeks) AND

2. Patient's transferrin saturation and serum ferritin have been evaluated

Drug is also subject to Part B versus Part D review.

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

1 month for surgery (reduce transfusion possibility), 6 months for chemo, 12 months for other

**Other Criteria:**

**Prior Authorization Group Description:**

Esbriet PA

**Drug Name(s)**

Pirfenidone

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of idiopathic pulmonary fibrosis (IPF) AND
2. Patient has no known explanation for interstitial lung disease (ILD) or pulmonary fibrosis (e.g., radiation, drugs, metal dusts, sarcoidosis, or any connective tissue disease known to cause ILD)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of idiopathic pulmonary fibrosis (IPF) AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., pathologist, pulmonologist, radiologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Fentanyl Oral PA - Fentanyl lozenge

**Drug Name(s)**

Fentanyl Citrate Oral Transmucosal

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. ONE of the following:

a. Patient has a documented diagnosis (i.e., medical records) of chronic cancer pain due to an active malignancy AND the following:

i. There is evidence of a claim that the patient is currently taking a long-acting opioid with the oral fentanyl within the past 90 days OR

b. Patient has a diagnosis that is supported in CMS approved compendia for the requested agent AND

2. Patient will NOT be using the requested agent in combination with any other oral or nasal fentanyl agent

**Age Restriction:**

Patient is 16 years of age or over

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Fintepla PA

**Drug Name(s)**

Fintepla

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of seizures associated with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS) AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient has been treated with the requested agent OR
  - C. ALL of the following:
    - i. An echocardiogram assessment will be obtained before and during treatment with the requested agent, to evaluate for valvular heart disease and pulmonary arterial hypertension AND
    - ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis AND
    - iii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Gammagard/Gammaked/Gamunex-C PA

**Drug Name(s)**

Gamunex-C

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ONE of the following:

1. Patient has ONE of the following diagnoses:

A. Primary immunodeficiency [e.g., congenital agammaglobulinemia, common variable immunodeficiency (CVID), severe combined immunodeficiency, Wiskott-Aldrich Syndrome, X-linked agammaglobulinemia (XLA), humoral immunodeficiency, IgG subclass deficiency with or without IgA deficiency] OR

B. B-cell chronic lymphocytic leukemia OR multiple myeloma AND ONE of the following:

i. Patient has a history of infections OR

ii. Patient has evidence of specific antibody deficiency OR

iii. Patient has hypogammaglobulinemia OR

C. Idiopathic thrombocytopenia purpura AND ONE of the following:

i. Patient has failed ONE conventional therapy [e.g., corticosteroids (e.g., methylprednisolone), or immunosuppressants (e.g., azathioprine)] OR

ii. Patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR

D. Dermatomyositis AND ONE of the following:

i. Patient has failed ONE conventional therapy [e.g., corticosteroids (e.g., methylprednisolone) or immunosuppressants (e.g., azathioprine)] OR

ii. Patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR

E. Polymyositis AND ONE of the following:

i. Patient has failed ONE conventional therapy [e.g., corticosteroids (e.g., methylprednisolone) or immunosuppressants (e.g., azathioprine)] OR

ii. Patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR

F. Severe rheumatoid arthritis AND ONE of the following:

i. Patient has failed ONE conventional therapy [e.g., tumor necrosis factor antagonists (e.g., Humira), DMARDs (e.g., methotrexate), infliximab] OR

ii. Patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR

Criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**



Approval will be for 6 months for indications in Other Criteria, 12 months for all others

**Other Criteria:**

G. Myasthenia gravis (MG) AND ONE of the following:

- i. Patient is in acute myasthenic crisis OR
- ii. Patient has severe refractory MG (e.g., major functional disability/weakness) AND ONE of the following:
  - a) Patient has failed ONE immunomodulator therapy (i.e., corticosteroid, pyridostigmine, or azathioprine) OR
  - b) Patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to ONE immunomodulator therapy OR

H. Multiple sclerosis (MS) AND BOTH of the following:

- i. Patient has a diagnosis of relapsing remitting MS (RRMS) AND
- ii. Patient has had an insufficient response, documented failure, or FDA labeled contraindication(s) to TWO MS agents (e.g., Betaseron, Copaxone, dimethyl fumarate) OR

I. Acquired von Willebrand hemophilia AND ONE of the following:

- i. Patient has failed ONE conventional therapy (e.g., desmopressin solution, von Willebrand factor replacement therapy, corticosteroids, cyclophosphamide, FEIBA, rituximab, or recombinant factor VIIa) OR
- ii. Patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR

J. Refractory pemphigus vulgaris AND ONE of the following:

- i. Patient has failed ONE conventional immunosuppressive therapy (e.g., azathioprine, cyclophosphamide, mycophenolate, corticosteroids) OR
- ii. Patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional immunosuppressive therapy OR

2. ONE of the following:

- A. Patient has another FDA labeled indication for the requested agent OR
- B. Patient has an indication that is supported in CMS approved compendia for the requested agent

Indications with 6 months approval duration: Acquired von Willebrand hemophilia, Guillain-Barre Syndrome, Lambert-Eaton myasthenia syndrome, Kawasaki disease, CMV induced pneumonitis in solid organ transplant, Toxic shock syndrome due to invasive group A streptococcus, Toxic epidermal necrolysis and Stevens-Johnson syndrome

Drug is also subject to Part B versus Part D review.

**Prior Authorization Group Description:**

Gattex PA

**Drug Name(s)**

Gattex

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of short bowel syndrome (SBS) AND
2. Patient is dependent on parenteral nutrition OR intravenous (PN/IV) fluids AND
3. ONE of the following:
  - A. Patient is aged 1 year to 17 years AND BOTH of the following:
    - i. A fecal occult blood test has been performed within 6 months prior to initiating treatment with the requested agent AND
    - ii. ONE of the following:
      - a. There was no unexplained blood in the stool OR
      - b. There was unexplained blood in the stool AND a colonoscopy or a sigmoidoscopy was performed OR
  - B. Patient is 18 years of age or over AND BOTH of the following:
    - i. Patient has had a colonoscopy within 6 months prior to initiating treatment with the requested agent AND
    - ii. If polyps were present at this colonoscopy, the polyps were removed

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of short bowel syndrome (SBS) AND
3. Patient has had a reduction from baseline in parenteral nutrition OR intravenous (PN/IV) fluids

**Age Restriction:**

**Prescriber Restrictions:**

Prescriber is a specialist (e.g., gastroenterologist) or the prescriber has consulted with a specialist

**Coverage Duration:**

Approval will be 6 months for initial, 12 months for renewal

**Other Criteria:**

**Prior Authorization Group Description:**

Gaucher Enzyme Replacement PA – Cerezyme

**Drug Name(s)**

Cerezyme

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of Gaucher disease type 1 (GD1) confirmed by ONE of the following:
  - A. A baseline glucocerebrosidase enzyme activity of less than or equal to 15% of mean normal in peripheral blood leukocytes, fibroblasts, or other nucleated cells OR
  - B. Confirmation of genetic mutation of GBA gene with two disease-causing alleles AND
2. Prescriber has drawn baseline measurements of hemoglobin, platelet count, liver volume, and spleen volume AND
3. Prior to any treatment for the intended diagnosis, the patient has had at least ONE of the following clinical presentations:
  - A. Anemia [defined as mean hemoglobin (Hb) level below the testing laboratory's lower limit of the normal range based on age and gender] OR
  - B. Thrombocytopenia (defined as a platelet count of less than 100,000 per microliter) OR
  - C. Hepatomegaly OR
  - D. Splenomegaly OR
  - E. Growth failure (i.e., growth velocity below the standard mean for age) OR
  - F. Evidence of bone disease with other causes ruled out

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Gaucher disease type 1 (GD1) AND
3. Patient has had improvement and/or stabilization from baseline in at least ONE of the following:
  - A. Hemoglobin (Hb) level OR
  - B. Platelet count OR
  - C. Liver volume OR
  - D. Spleen volume OR
  - E. Growth velocity OR
  - F. Bone pain or disease

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, geneticist, hematologist, specialist in metabolic diseases) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Gaucher Enzyme Replacement PA – Elelyso

**Drug Name(s)**

Elelyso

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of Gaucher disease type 1 (GD1) confirmed by ONE of the following:
  - A. A baseline glucocerebrosidase enzyme activity of less than or equal to 15% of mean normal in peripheral blood leukocytes, fibroblasts, or other nucleated cells OR
  - B. Confirmation of genetic mutation of GBA gene with two disease-causing alleles AND
2. Prescriber has drawn baseline measurements of hemoglobin, platelet count, liver volume, and spleen volume AND
3. Prior to any treatment for the intended diagnosis, the patient has had at least ONE of the following clinical presentations:
  - A. Anemia [defined as mean hemoglobin (Hb) level below the testing laboratory's lower limit of the normal range based on age and gender] OR
  - B. Thrombocytopenia (defined as a platelet count of less than 100,000 per microliter) OR
  - C. Hepatomegaly OR
  - D. Splenomegaly OR
  - E. Growth failure (i.e., growth velocity below the standard mean for age) OR
  - F. Evidence of bone disease with other causes ruled out

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Gaucher disease type 1 (GD1) AND
3. Patient has had improvement and/or stabilization from baseline in at least ONE of the following:
  - A. Hemoglobin (Hb) level OR
  - B. Platelet count OR
  - C. Liver volume OR
  - D. Spleen volume OR
  - E. Growth velocity OR
  - F. Bone pain or disease

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, geneticist, hematologist, specialist in metabolic diseases) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Gaucher Enzyme Replacement PA – Vpriv

**Drug Name(s)**

Vpriv

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of Gaucher disease type 1 (GD1) confirmed by ONE of the following:
  - A. A baseline glucocerebrosidase enzyme activity of less than or equal to 15% of mean normal in peripheral blood leukocytes, fibroblasts, or other nucleated cells OR
  - B. Confirmation of genetic mutation of GBA gene with two disease-causing alleles AND
2. Prescriber has drawn baseline measurements of hemoglobin, platelet count, liver volume, and spleen volume AND
3. Prior to any treatment for the intended diagnosis, the patient has had at least ONE of the following clinical presentations:
  - A. Anemia [defined as mean hemoglobin (Hb) level below the testing laboratory's lower limit of the normal range based on age and gender] OR
  - B. Thrombocytopenia (defined as a platelet count of less than 100,000 per microliter) OR
  - C. Hepatomegaly OR
  - D. Splenomegaly OR
  - E. Growth failure (i.e., growth velocity below the standard mean for age) OR
  - F. Evidence of bone disease with other causes ruled out

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Gaucher disease type 1 (GD1) AND
3. Patient has had improvement and/or stabilization from baseline in at least ONE of the following:
  - A. Hemoglobin (Hb) level OR
  - B. Platelet count OR
  - C. Liver volume OR
  - D. Spleen volume OR
  - E. Growth velocity OR
  - F. Bone pain or disease

**Age Restriction:**

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, geneticist, hematologist, specialist in metabolic diseases) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Growth Hormone PA – Omnitrope

**Drug Name(s)**

Omnitrope

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindication(s) to the requested agent

**Required Medical Information:**

For Children – Criteria for initial approval require the following:

1. ONE of the following:
  - a. Patient is 4 months of age or younger with hypoglycemia in the absence of metabolic disorder AND
    - i. The GH level is less than 20 ng/mL OR
  - b. Patient has a diagnosis of Turner Syndrome OR
  - c. Patient has a diagnosis of Prader-Willi Syndrome OR
  - d. Patient has a diagnosis of panhypopituitarism AND BOTH of the following:
    - i. Deficiencies in 3 or more pituitary axes AND
    - ii. Measured serum IGF-1 (insulin-like growth factor-1) levels are below the age and sex-appropriate reference range when off GH therapy OR
  - e. Patient has a diagnosis of growth hormone deficiency (GHD) or short stature AND BOTH of the following:
    - i. Patient has ONE of the following:
      - a) Height more than 2 standard deviations (SD) below the mean for age and sex OR
      - b) Height more than 1.5 SD below the midparental height OR
      - c) A decrease in height SD of more than 0.5 over one year in children at least 2 years of age OR
      - d) Height velocity more than 2 SD below the mean over one year or more than 1.5 SD sustained over two years AND
    - ii. Failure of at least 2 growth hormone (GH) stimulation tests (e.g., peak GH value of less than 10 mcg/L after stimulation, or otherwise considered abnormal as determined by testing lab) OR
  - f. Patient has a diagnosis of small for gestational age (SGA) AND ALL of the following:
    - i. Patient is at least 2 years of age AND
    - ii. Documented birth weight and/or length that is 2 or more standard deviations (SD) below the mean for gestational age AND
    - iii. At 24 months of age, the patient fails to manifest catch-up growth evidenced by a height that remains 2 or more SD below the mean for age and sex

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

For Children – Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the preferred agent through the plan's Prior Authorization criteria AND

2. Patient has been diagnosed with ONE of the following:
  - a. 4 months of age or younger with hypoglycemia in the absence of metabolic disorder OR
  - b. Growth Hormone Deficiency, Short Stature OR
  - c. Panhypopituitarism OR
  - d. Prader-Willi Syndrome OR
  - e. Small for Gestational Age (SGA) OR
  - f. Turner Syndrome AND
3. ALL of the following:
  - a. Patient does not have closed epiphyses AND
  - b. Patient is being monitored for adverse effects of therapy with the requested agent AND
  - c. Patient's height is increased or height velocity has improved since initiation or last approval of the requested agent

For Adults – Criteria for initial approval require the following:

1. Patient has been diagnosed with ONE of the following:
  - a. Childhood growth hormone deficiency (GHD) with genetic or organic origin AND ONE of the following:
    - i. Low IGF-1 (insulin-like growth factor-1) level without GH replacement therapy OR
    - ii. Failure of at least one growth hormone (GH) stimulation test as an adult (e.g., peak GH value of 5 mcg/L or lower after stimulation, or otherwise considered abnormal as determined by testing lab) OR
  - b. Acquired adult GHD secondary to structural lesions or trauma AND ONE of the following:
    - i. Patient has a diagnosis of panhypopituitarism AND BOTH of the following:
      - a) Deficiencies in 3 or more pituitary axes AND
      - b) Low IGF-1 level without GH replacement therapy OR
    - ii. Patient has failed at least one growth hormone (GH) stimulation test as an adult OR
  - c. Idiopathic GHD (adult or childhood onset) AND the patient has failed at least two growth hormone (GH) stimulation tests as an adult

For Adults – Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the preferred agent through the plan's Prior Authorization criteria AND
2. Patient has been diagnosed with ONE of the following:
  - a. Childhood growth hormone deficiency (GHD) with genetic or organic origin OR
  - b. Acquired adult GHD secondary to structural lesions or trauma OR
  - c. Other (e.g., childhood idiopathic GHD, adult-onset idiopathic GHD) AND
3. Patient is being monitored for adverse effects of therapy with the requested agent AND
4. Patient's IGF-1 level has been evaluated to confirm the appropriateness of the current dose AND
5. Patient has had benefits from therapy with the requested agent in any of the following response parameters: body composition, hip-to-waist ratio, cardiovascular health, bone mineral density, serum cholesterol, physical strength, or quality of life

**Prior Authorization Group Description:**

HAE PA – Haegarda

**Drug Name(s)**

Haegarda

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of hereditary angioedema (HAE) which has been confirmed via two confirmatory tests of C1-INH antigenic level, C1-INH functional level, and C4 level as follows:
  - a. Type I HAE: decreased quantities of C4 and C1-INH OR
  - b. Type II HAE: decreased quantities of C4 and C1-INH function (C1-INH protein level may be normal) OR
  - c. Type III HAE: Normal levels of C4 and C1-INH (at baseline and during an attack) AND ONE of the following:
    - i. BOTH of the following:
      1. Family history of angioedema AND
      2. ALL other causes of angioedema have been ruled out OR
    - ii. Patient demonstrates a Factor XII mutation, angiotensin-converting enzyme 1 (ACE) mutation, or plasminogen (PLG) mutation that is associated with the disease AND
2. Medications known to cause angioedema (e.g., ACE-Inhibitors, estrogens, angiotensin II receptor blockers) have been evaluated and discontinued when appropriate AND
3. The requested agent will be used for prophylaxis against HAE attacks AND
4. Patient will NOT be using the requested agent in combination with another HAE agent indicated for prophylaxis against HAE attacks

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of hereditary angioedema (HAE) AND
3. The requested agent is being used for prophylaxis against HAE attacks AND
4. Patient has had a decrease in the frequency or severity of acute attacks or has had stabilization of disease from use of the requested agent AND
5. Patient will NOT be using the requested agent in combination with another HAE agent indicated for prophylaxis against HAE attacks

**Prior Authorization Group Description:**

HAE PA – Icatibant

**Drug Name(s)**

Icatibant Citrate

Sajazir

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of hereditary angioedema (HAE) which has been confirmed via two confirmatory tests of C1-INH antigenic level, C1-INH functional level, and C4 level as follows:
  - a. Type I HAE: decreased quantities of C4 and C1-INH OR
  - b. Type II HAE: decreased quantities of C4 and C1-INH function (C1-INH protein level may be normal) OR
  - c. Type III HAE: Normal levels of C4 and C1-INH (at baseline and during an attack) AND ONE of the following:
    - i. BOTH of the following:
      1. Family history of angioedema AND
      2. ALL other causes of angioedema have been ruled out OR
    - ii. Patient demonstrates a Factor XII mutation, angiotensin-converting enzyme (ACE) mutation, or plasminogen (PLG) mutation that is associated with the disease AND
      2. Medications known to cause angioedema (e.g., ACE-Inhibitors, estrogens, angiotensin II receptor blockers) have been evaluated and discontinued when appropriate AND
      3. The requested agent will be used to treat acute HAE attacks AND
      4. Patient will NOT be using the requested agent in combination with another HAE agent indicated for treatment of acute HAE attacks

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of hereditary angioedema (HAE) AND
3. The requested agent will be used to treat acute HAE attacks AND
4. Patient will NOT be using the requested agent in combination with another HAE agent indicated for treatment of acute HAE attacks AND
5. Patient has had a decrease in the frequency or severity of acute attacks or stabilization of disease from use of the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Harvoni PA

**Drug Name(s)**

Harvoni

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of hepatitis C confirmed by serological markers AND
2. Prescriber has screened the patient for current or prior hepatitis B viral (HBV) infection and if positive, will monitor the patient for HBV flare-up or reactivation during and after treatment with the requested agent AND
3. The requested agent will be used in a treatment regimen and length of therapy that is supported in FDA approved labeling or AASLD/IDSA guidelines for the patient's diagnosis and genotype AND
4. The dosing of the requested agent is within the FDA labeled dosing or supported in AASLD/IDSA dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, hepatologist or infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Duration of therapy: Based on FDA approved labeling or AASLD/IDSA guideline supported

**Other Criteria:**

**Prior Authorization Group Description:**

Hetlioz Capsule PA

**Drug Name(s)**

Hetlioz

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. Patient has a diagnosis of Non-24-hour sleep-wake disorder AND

ii. Patient is totally blind (i.e., no light perception) AND

B. BOTH of the following:

i. Patient has a diagnosis of Smith-Magenis Syndrome (SMS) confirmed by the presence of ONE of the following genetic mutations:

A. A heterozygous deletion of 17p11.2 OR

B. A heterozygous pathogenic variant involving RAI1 AND

ii. The requested agent is being used to treat nighttime sleep disturbances associated with SMS

**Age Restriction:**

For diagnosis of Non-24-hour sleep-wake disorder, patient is 18 years of age or over. For diagnosis of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), patient is 16 years of age or older.

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist, sleep specialist, psychiatrist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

High Risk Medication PA - All Starts

**Drug Name(s)**

Benztropine Mesylate

Clemastine Fumarate

Dicyclomine Hydrochloride

Promethazine Hcl

Promethazine Hcl Plain

Promethazine Hydrochloride

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require ALL of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested high-risk medication AND
2. Prescriber has indicated that the benefits of the requested high-risk medication outweigh the risks for the patient AND
3. Prescriber has documented that s/he discussed risks and potential side effects of the requested high-risk medication with the patient

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

High Risk Medication PA – Cyclobenzaprine

**Drug Name(s)**

Cyclobenzaprine Hydrochloride

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested medication AND

2. If the patient is 65 years of age or over, then ALL of the following:

A. ONE of the following:

i. Patient has fibromyalgia and has tried and had an inadequate response to both duloxetine and pregabalin OR

ii. Patient has fibromyalgia and has an intolerance or hypersensitivity to both duloxetine and pregabalin OR

iii. Patient has fibromyalgia and has an FDA labeled contraindication to both duloxetine and pregabalin OR

iv. Patient has a diagnosis other than fibromyalgia which does NOT require any prerequisites AND

B. Prescriber has indicated that the benefits of the requested high-risk medication outweigh the risks for the patient AND

C. Prescriber has documented that s/he discussed risks and potential side effects of the requested high-risk medication with the patient

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

High Risk Medication PA - New Starts

**Drug Name(s)**

Megestrol Acetate

Paroxetine Hcl

Paroxetine Hydrochloride

Paxil

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require ONE of the following:

1. BOTH of the following:

A. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested high-risk medication AND

B. ONE of the following:

i. There is evidence of a claim that the patient has been treated with the requested high-risk medication within the past 180 days OR

ii. Prescriber states the patient has been treated with the requested high-risk medication OR

2. ALL of the following:

A. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested high-risk medication AND

B. Prescriber has indicated that the benefits of the requested high-risk medication outweigh the risks for the patient AND

C. Prescriber has documented that s/he discussed risks and potential side effects of the requested high-risk medication with the patient

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Ilaris PA

**Drug Name(s)**

Ilaris

**Indications:**

All FDA-Approved Indications, Some Medically-Accepted Indications.

**Off-Label Uses:**

Acute gouty arthritis

**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of:

1. ONE of the following:

A. Patient (pt) has been diagnosed with Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) OR

B. Pt has been diagnosed with Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) OR

C. Pt has been diagnosed with Familial Mediterranean Fever (FMF) AND ONE of the following:

i. Pt has tried and had an inadequate response to colchicine OR

ii. Pt has an intolerance or hypersensitivity to colchicine OR

iii. Pt has an FDA labeled contraindication to colchicine OR

D. Pt has been diagnosed with Cryopyrin-Associated Periodic Syndrome (CAPS) including Familial Cold Auto-inflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS) OR

E. Pt has been diagnosed with active Systemic Juvenile Idiopathic Arthritis (SJIA) AND BOTH of the following:

i. Pt has documented active systemic features (e.g., ongoing fever, evanescent erythematous rash, generalized lymphadenopathy, 1 or more joints with active arthritis, hepatomegaly, splenomegaly, serositis) AND

ii. ONE of the following:

a. Pt has tried and had an inadequate response to at least ONE prerequisite agent (e.g., glucocorticosteroids, prescription oral NSAIDs, methotrexate, leflunomide, Enbrel) OR

b. Pt has an intolerance or hypersensitivity to at least ONE prerequisite agent OR

c. Pt has an FDA labeled contraindication to at least ONE prerequisite agent OR

F. Pt has a diagnosis of adult onset Still's disease OR

G. Pt has been diagnosed with acute gouty arthritis AND ONE of the following:

i. Pt has tried and had an inadequate response to at least TWO conventional first-line agents (e.g., prescription oral NSAIDs, colchicine, systemic corticosteroids) OR

ii. Pt has an intolerance or hypersensitivity to at least TWO conventional first-line agents OR

iii. Pt has an FDA labeled contraindication to at least TWO conventional first-line agents AND

2. Pt will NOT be using the requested agent in combination with another biologic agent

**Age Restriction:**

For diagnosis of CAPS including FCAS or MWS, patient is 4 years of age or over. For diagnosis of SJIA, patient is 2 years of age or over.

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Imiquimod PA

**Drug Name(s)**

Imiquimod

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has ONE of the following diagnoses:

A. Actinic keratosis OR

B. Superficial basal cell carcinoma OR

C. External genital and/or perianal warts/condyloma acuminata OR

D. Squamous cell carcinoma OR

E. Basal cell carcinoma OR

F. Another indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

4 months for Actinic keratosis, other diagnoses - see Other Criteria

**Other Criteria:**

2 months for Superficial basal cell carcinoma, Squamous cell carcinoma, and Basal cell carcinoma

4 months for External genital and/or perianal warts/condyloma acuminata

12 months for All other diagnoses

**Prior Authorization Group Description:**

Injectable Oncology PA

**Drug Name(s)**

Abraxane  
Adcetris  
Aliqopa  
Alymsys  
Arranon  
Arzerra  
Avastin  
Beleodaq  
Besponsa  
Blenrep  
Blincyto  
Bortezomib  
Cycramza  
Danyelza  
Darzalex  
Darzalex Faspro  
Doxorubicin Hydrochloride Liposome  
Empliciti  
Enhertu  
Erbix  
Folotyn  
Fulvestrant  
Gazyva  
Halaven  
Herceptin  
Herceptin Hylecta  
Herzuma  
Jevtana  
Kadcyla  
Kanjinti  
Kyprolis  
Lumoxiti  
Margenza  
Monjuvi

Mvasi  
Mylotarg  
Nelarabine  
Ogivri  
Onivyde  
Ontruzant  
Padcev  
Pemetrexed  
Perjeta  
Phesgo  
Polivy  
Portrazza  
Poteligeo  
Romidepsin  
Rybrevant  
Sarclisa  
Synribo  
Trazimera  
Trodelvy  
Unituxin  
Vectibix  
Velcade  
Vyxeos  
Yondelis  
Zaltrap  
Zepzelca  
Zirabev  
Zynlonta

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:

- A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR
- B. Prescriber states the patient has been treated with the requested agent OR
- C. ALL of the following:
  - i. Genetic testing has been completed, if required, for therapy with the requested agent and results indicate the requested agent is appropriate AND
  - ii. ONE of the following:
    - a. Patient has tried appropriate FDA labeled or compendia supported therapy that are indicated in NCCN as first-line therapy OR
    - b. Patient has an intolerance or hypersensitivity to the first-line therapy for the requested indication OR
    - c. Patient has an FDA labeled contraindication to the first-line therapy for the requested indication AND
  - iii. Patient does NOT have any FDA labeled contraindications to the requested agent AND
  - iv. Patient does NOT have any FDA labeled limitations of use that is not otherwise supported in NCCN guidelines

May also be subject to Part B versus Part D review.

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Iron Chelating Agents PA – Exjade

**Drug Name(s)**

Deferasirox (Exjade)

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of chronic iron overload due to a non-transfusion dependent thalassemia syndrome AND ONE of the following:

i. A liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight OR

ii. A serum ferritin greater than 300 mcg/L OR

iii. MRI confirmation of iron deposition OR

B. Patient has a diagnosis of chronic iron overload due to blood transfusions

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of chronic iron overload due to a non-transfusion dependent thalassemia syndrome OR

B. Patient has a diagnosis of chronic iron overload due to blood transfusions AND

3. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent for the requested indication

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Iron Chelating Agents PA – Jadenu

**Drug Name(s)**

Deferasirox (Jadenu)

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of chronic iron overload due to a non-transfusion dependent thalassemia syndrome AND ONE of the following:

i. A liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight OR

ii. A serum ferritin greater than 300 mcg/L OR

iii. MRI confirmation of iron deposition OR

B. Patient has a diagnosis of chronic iron overload due to blood transfusions

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of chronic iron overload due to a non-transfusion dependent thalassemia syndrome OR

B. Patient has a diagnosis of chronic iron overload due to blood transfusions AND

3. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent for the requested indication

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Kalydeco PA

**Drug Name(s)**

Kalydeco

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of cystic fibrosis AND
2. ONE of the following:
  - A. Patient has ONE of the CFTR gene mutations or a mutation in the CFTR gene that is responsive based on in vitro data, as indicated in the FDA label, confirmed by genetic testing OR
  - B. Patient has another CFTR gene mutation(s) that is responsive to the requested agent AND
3. Patient is NOT homozygous for the F508del mutation AND
4. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of cystic fibrosis AND
3. Patient has had improvement or stabilization with the requested agent [e.g., improvement in FEV1 from baseline, increase in weight/BMI, improvement from baseline Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain score, improvements in respiratory symptoms (cough, sputum production, and difficulty breathing), and/or reduced number of pulmonary exacerbations] AND
4. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cystic fibrosis, pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Kerendia PA

**Drug Name(s)**

Kerendia

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient is currently receiving the following standard of care background therapy with the requested agent
  - A. A maximally tolerated dose of ACE inhibitor, ARB, or a combination medication containing an ACE or ARB AND
  - B. Antidiabetic agent (e.g., metformin or an agent containing metformin, SGLT2 inhibitor, GLP-1 RA)

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Korlym PA

**Drug Name(s)**

Korlym

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindication(s) to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of Cushing's syndrome AND
2. ONE of the following:
  - A. Patient has type 2 diabetes mellitus OR
  - B. Patient has glucose intolerance as defined by a 2-hour glucose tolerance test plasma glucose value of 140-199 mg/dL AND
3. ONE of the following:
  - A. Patient has failed surgical resection OR
  - B. Patient is NOT a candidate for surgical resection

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Leuprolide PA

**Drug Name(s)**

Eligard

Leuprolide Acetate

Lupron Depot (1-Month)

Lupron Depot (3-Month)

Lupron Depot (4-Month)

Lupron Depot (6-Month)

Lupron Depot-Ped (1-Month)

Lupron Depot-Ped (3-Month)

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. ONE of the following:

a. Patient has an FDA labeled indication for the requested agent OR

b. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

2. ONE of the following:

a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR

b. Prescriber states the patient is currently being treated with the requested agent OR

c. BOTH of the following:

i. Patient is NOT currently being treated with the requested agent AND

ii. Patient does NOT have any FDA labeled contraindication(s) to the requested agent AND

3. The requested dose is within the FDA labeled or CMS approved compendia dosing for the requested indication

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Lidocaine Topical PA - Lidocaine Gel/Jelly

**Drug Name(s)**

Glydo

Lidocaine Hcl

Lidocaine Hcl Jelly

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require the following:

1. The requested agent will be used for ONE of the following:

A. Surface anesthesia and lubrication for urethral procedure OR

B. Topical treatment for pain of urethritis OR

C. Surface anesthesia and lubrication for endotracheal intubation (oral and nasal) OR

D. Another indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Lidocaine Topical PA - Lidocaine Patch

**Drug Name(s)**

Lidocaine

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has ONE of the following diagnoses:

A. Pain associated with postherpetic neuralgia (PHN) OR

B. Pain associated with diabetic neuropathy OR

C. Neuropathic pain associated with cancer, or cancer treatment OR

D. Another diagnosis that is supported in CMS approved compendia for the requested agent AND

2. ONE of the following:

A. Patient's medication history includes use of a conventional therapy [e.g., gabapentin, pregabalin, oral prescription NSAID (non-steroidal anti-inflammatory drug)] for the requested indication OR

B. Patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to a conventional therapy

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Lidocaine Topical PA - Lidocaine Solution

**Drug Name(s)**

Lidocaine Hydrochloride

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require the following:

1. The requested agent will be used for ONE of the following:
  - A. Topical anesthesia of accessible mucous membranes of the oral and nasal cavities OR
  - B. Topical anesthesia of accessible mucous membranes of proximal portions of the digestive tract OR
  - C. Another indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Lidocaine Topical PA - Lidocaine/prilocaine Cream

**Drug Name(s)**

Lidocaine/Prilocaine

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require the following:

1. The requested agent will be used for ONE of the following:

A. Local analgesia on normal intact skin OR

B. Topical anesthetic for dermal procedures OR

C. Adjunctive anesthesia prior to local anesthetic infiltration in adult male genital skin OR

D. Anesthesia for minor procedures on female external genitalia OR

E. Another indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Linezolid PA

**Drug Name(s)**

Linezolid

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindication(s) to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. ONE of the following:

- a. The requested agent is prescribed by an infectious disease specialist or the prescriber has consulted with an infectious disease specialist on treatment of this patient AND the patient has an FDA labeled indication for the requested agent OR
- b. Patient has a documented infection due to vancomycin-resistant *Enterococcus faecium* OR
- c. Patient has a diagnosis of pneumonia caused by *Staphylococcus aureus* or *Streptococcus pneumoniae* AND ONE of the following:
  - i. Patient has a documented infection that is resistant to at least two of the following: beta lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole, OR that is resistant to vancomycin OR
  - ii. Patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to at least two of the following: beta lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole OR
  - iii. Patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to vancomycin OR
- d. Patient has a documented skin and skin structure infection, including diabetic foot infections, caused by *Staphylococcus aureus*, *Streptococcus pyogenes*, or *Streptococcus agalactiae* AND ONE of the following:
  - i. Patient has a documented infection that is resistant to at least two of the following: beta lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole, OR that is resistant to vancomycin at the site of infection OR
  - ii. Patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to at least two of the following: beta lactams, macrolides, clindamycin, tetracyclines or co-trimoxazole OR
  - iii. Patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to vancomycin AND

Criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 3 months

**Other Criteria:**

2. ONE of the following:

- a. Patient is NOT currently being treated for the same infection with Sivextro (tedizolid) OR

- b. The current treatment with Sivextro (tedizolid) for the same infection will be discontinued before starting therapy with the requested agent AND
- 3. The requested dose is within the FDA labeled dosing for the requested indication

**Prior Authorization Group Description:**

Memantine PA

**Drug Name(s)**

Memantine Hcl Titration Pak

Memantine Hydrochloride

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

PA does NOT apply to patients greater than or equal to 30 years of age

Criteria for approval require the following:

1. Patient is younger than 30 years of age AND ONE of the following:

A. Patient has a diagnosis of moderate to severe dementia of the Alzheimer's type OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Modafinil PA

**Drug Name(s)**

Modafinil

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. ONE of the following:

A. Patient has an FDA labeled indication for the requested agent OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

2. Patient will NOT be using the requested agent in combination with another target agent (i.e., armodafinil)

**Age Restriction:**

Patient is 17 years of age or over

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Movantik PA

**Drug Name(s)**

Movantik

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindication(s) to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has opioid-induced constipation (OIC) and chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment AND
2. Patient has chronic use of an opioid agent in the past 90 days AND
3. ONE of the following:
  - A. Patient has tried and had an inadequate response to lactulose OR
  - B. Patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to lactulose

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

MS PA – Betaseron

**Drug Name(s)**

Betaseron

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) for the requested indication

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

MS PA - Dimethyl Fumarate

**Drug Name(s)**

Dimethyl Fumarate

Dimethyl Fumarate Starterpack

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) for the requested indication

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

MS PA – Glatiramer

**Drug Name(s)**

Copaxone

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) for the requested indication

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

MS PA – Tysabri

**Drug Name(s)**

Tysabri

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient has been treated with the requested agent AND is at risk if therapy is changed OR
  - C. The patient has ONE of the following diagnoses:
    - i. Relapsing form of Multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease AND ONE of the following:
      - a. Prescriber states the patient has highly active disease OR
      - b. ONE of the following:
        1. Patient has tried and had an inadequate response to TWO preferred agents (Betaseron, Copaxone, dimethyl fumarate) OR
        2. Patient has an intolerance or hypersensitivity to TWO preferred agents (Betaseron, Copaxone, dimethyl fumarate) OR
        3. Patient has an FDA labeled contraindication to TWO preferred agents (Betaseron, Copaxone, dimethyl fumarate) OR
      - ii. Moderately to severely active Crohn’s disease (CD) AND BOTH of the following:
        - a. ONE of the following:
          1. Patient has tried and had an inadequate response to ONE conventional CD therapy (e.g., 6-mercaptopurine, azathioprine, corticosteroids, methotrexate, sulfasalazine) OR
          2. Patient has an intolerance or hypersensitivity to ONE conventional CD therapy (e.g., 6-mercaptopurine, azathioprine, corticosteroids, methotrexate, sulfasalazine) OR
          3. Patient has an FDA labeled contraindication to ONE conventional CD therapy (e.g., 6-mercaptopurine, azathioprine, corticosteroids, methotrexate, sulfasalazine) AND

Initial criteria continues: see Other Criteria

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months for MS, for CD 16 weeks for initial and 12 months renewal

**Other Criteria:**

- b. ONE of the following:

1. Patient has tried and had an inadequate response to ONE preferred biologic agent (Humira or Stelara) for the treatment of CD OR
2. Patient has an intolerance or hypersensitivity to ONE preferred biologic agent (Humira or Stelara) OR
3. Patient has an FDA labeled contraindication to ONE preferred biologic agent (Humira or Stelara) AND
3. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) for the requested indication

**Prior Authorization Group Description:**

Natpara PA

**Drug Name(s)**

Natpara

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

Increased baseline risk for osteosarcoma (e.g., Paget's disease of bone, unexplained elevations of alkaline phosphatase, hereditary disorders predisposing to osteosarcoma, history of external beam or implant radiation therapy involving the skeleton, pediatric and young adult patients with open epiphyses)

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of hypocalcemia associated with hypoparathyroidism AND
2. Patient does NOT have a baseline vitamin D level below the testing laboratory's lower limit of normal AND
3. Patient's baseline serum calcium level (albumin-corrected) is above 7.5 mg/dL AND
4. ONE of the following:
  - A. Patient is NOT currently being treated with alendronate OR
  - B. Patient is currently being treated with alendronate AND will discontinue prior to initiating therapy with the requested agent

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of hypocalcemia associated with hypoparathyroidism AND
3. Patient has shown clinical benefit with the requested agent AND
4. Patient has a serum calcium level (albumin-corrected) between 7.5 mg/dL and 10.6 mg/dL AND
5. ONE of the following:
  - A. Patient is NOT currently being treated with alendronate OR
  - B. Patient is currently being treated with alendronate and will discontinue prior to continuing therapy with the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist (e.g., endocrinologist, nephrologist) or the prescriber has consulted with a specialist

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Nuedexta PA

**Drug Name(s)**

Nuedexta

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of pseudobulbar affect AND
2. Patient will NOT be using the requested agent in combination with a monoamine oxidase inhibitor (MAOI) [e.g., Marplan (isocarboxazid), Nardil (phenelzine), and Parnate (tranylcypromine)]

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Nuplazid PA

**Drug Name(s)**

Nuplazid

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Ofev PA

**Drug Name(s)**

Ofev

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:
  - A. BOTH of the following:
    - i. Patient has a diagnosis of idiopathic pulmonary fibrosis (IPF) AND
    - ii. Patient has no known explanation for interstitial lung disease (ILD) or pulmonary fibrosis (e.g., radiation, drugs, metal dusts, sarcoidosis, or any connective tissue disease known to cause ILD) OR
  - B. BOTH of the following:
    - i. Patient has a diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD) AND
    - ii. Patient's diagnosis has been confirmed on high-resolution computed tomography (HRCT) or chest radiography scans OR
  - C. BOTH of the following:
    - i. Patient has a diagnosis of chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype AND
    - ii. Patient's diagnosis has been confirmed on high-resolution computed tomography (HRCT)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of ONE of the following:
  - A. Idiopathic pulmonary fibrosis (IPF) OR
  - B. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) OR
  - C. Chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., pathologist, pulmonologist, radiologist, rheumatologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Oncology Immunotherapy PA – Bavencio

**Drug Name(s)**

Bavencio

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient has been treated with the requested agent OR
  - C. ALL of the following:
    - i. Genetic testing has been completed, if required, for therapy with the requested agent and results indicate the requested agent is appropriate AND
    - ii. ONE of the following:
      - a. Patient has tried appropriate FDA labeled or compendia supported therapy that are indicated in NCCN as first-line therapy OR
      - b. Patient has an intolerance or hypersensitivity to the first-line therapy for the requested indication OR
      - c. Patient has an FDA labeled contraindication to the first-line therapy for the requested indication AND
    - iii. Patient does NOT have any FDA labeled limitations of use that is not otherwise supported in NCCN guidelines

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Oncology Immunotherapy PA – Imfinzi

**Drug Name(s)**

Imfinzi

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient has been treated with the requested agent OR
  - C. ALL of the following:
    - i. Genetic testing has been completed, if required, for therapy with the requested agent and results indicate the requested agent is appropriate AND
    - ii. ONE of the following:
      - a. Patient has tried appropriate FDA labeled or compendia supported therapy that are indicated in NCCN as first-line therapy OR
      - b. Patient has an intolerance or hypersensitivity to the first-line therapy for the requested indication OR
      - c. Patient has an FDA labeled contraindication to the first-line therapy for the requested indication AND
    - iii. Patient does NOT have any FDA labeled limitations of use that is not otherwise supported in NCCN guidelines

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Oncology Immunotherapy PA – Jemperli

**Drug Name(s)**

Jemperli

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND

2. ONE of the following:

A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR

B. Prescriber states the patient has been treated with the requested agent OR

C. ALL of the following:

i. Genetic testing has been completed, if required, for therapy with the requested agent and results indicate the requested agent is appropriate AND

ii. ONE of the following:

a. Patient has tried appropriate FDA labeled or compendia supported therapy that are indicated in NCCN as first-line therapy OR

b. Patient has an intolerance or hypersensitivity to the first-line therapy for the requested indication OR

c. Patient has an FDA labeled contraindication to the first-line therapy for the requested indication AND

iii. Patient does NOT have any FDA labeled limitations of use that is not otherwise supported in NCCN guidelines

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Oncology Immunotherapy PA – Keytruda

**Drug Name(s)**

Keytruda

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient has been treated with the requested agent OR
  - C. ALL of the following:
    - i. Genetic testing has been completed, if required, for therapy with the requested agent and results indicate the requested agent is appropriate AND
    - ii. ONE of the following:
      - a. Patient has tried appropriate FDA labeled or compendia supported therapy that are indicated in NCCN as first-line therapy OR
      - b. Patient has an intolerance or hypersensitivity to the first-line therapy for the requested indication OR
      - c. Patient has an FDA labeled contraindication to the first-line therapy for the requested indication AND
    - iii. Patient does NOT have any FDA labeled limitations of use that is not otherwise supported in NCCN guidelines

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Oncology Immunotherapy PA – Libtayo

**Drug Name(s)**

Libtayo

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND

2. ONE of the following:

A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR

B. Prescriber states the patient has been treated with the requested agent OR

C. ALL of the following:

i. Genetic testing has been completed, if required, for therapy with the requested agent and results indicate the requested agent is appropriate AND

ii. ONE of the following:

a. Patient has tried appropriate FDA labeled or compendia supported therapy that are indicated in NCCN as first-line therapy OR

b. Patient has an intolerance or hypersensitivity to the first-line therapy for the requested indication OR

c. Patient has an FDA labeled contraindication to the first-line therapy for the requested indication AND

iii. Patient does NOT have any FDA labeled limitations of use that is not otherwise supported in NCCN guidelines

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Oncology Immunotherapy PA – Opdivo

**Drug Name(s)**

Opdivo

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient has been treated with the requested agent OR
  - C. ALL of the following:
    - i. Genetic testing has been completed, if required, for therapy with the requested agent and results indicate the requested agent is appropriate AND
    - ii. ONE of the following:
      - a. Patient has tried appropriate FDA labeled or compendia supported therapy that are indicated in NCCN as first-line therapy OR
      - b. Patient has an intolerance or hypersensitivity to the first-line therapy for the requested indication OR
      - c. Patient has an FDA labeled contraindication to the first-line therapy for the requested indication AND
    - iii. Patient does NOT have any FDA labeled limitations of use that is not otherwise supported in NCCN guidelines

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Oncology Immunotherapy PA – Tecentriq

**Drug Name(s)**

Tecentriq

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND

2. ONE of the following:

A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR

B. Prescriber states the patient has been treated with the requested agent OR

C. ALL of the following:

i. Genetic testing has been completed, if required, for therapy with the requested agent and results indicate the requested agent is appropriate AND

ii. ONE of the following:

a. Patient has tried appropriate FDA labeled or compendia supported therapy that are indicated in NCCN as first-line therapy OR

b. Patient has an intolerance or hypersensitivity to the first-line therapy for the requested indication OR

c. Patient has an FDA labeled contraindication to the first-line therapy for the requested indication AND

iii. Patient does NOT have any FDA labeled limitations of use that is not otherwise supported in NCCN guidelines

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Oncology Immunotherapy PA – Yervoy

**Drug Name(s)**

Yervoy

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient has been treated with the requested agent OR
  - C. ALL of the following:
    - i. Genetic testing has been completed, if required, for therapy with the requested agent and results indicate the requested agent is appropriate AND
    - ii. ONE of the following:
      - a. Patient has tried appropriate FDA labeled or compendia supported therapy that are indicated in NCCN as first-line therapy OR
      - b. Patient has an intolerance or hypersensitivity to the first-line therapy for the requested indication OR
      - c. Patient has an FDA labeled contraindication to the first-line therapy for the requested indication AND
    - iii. Patient does NOT have any FDA labeled limitations of use that is not otherwise supported in NCCN guidelines

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Opioids ER PA - Fentanyl Patch

**Drug Name(s)**

Fentanyl

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of chronic cancer pain due to an active malignancy OR

B. Patient is undergoing treatment of chronic non-cancer pain AND ONE of the following:

i. There is evidence of a claim that indicates the patient has been treated with the requested agent within the past 90 days OR

ii. Prescriber states the patient has been treated with the requested agent within the past 90 days OR

iii. ALL of the following:

a. Prescriber has provided documentation of a formal, consultative evaluation including BOTH of the following:

1. Diagnosis AND

2. A complete medical history which includes previous and current pharmacological and non-pharmacological therapy AND

b. The requested agent is NOT prescribed as an as-needed (prn) analgesic AND

c. Prescriber has confirmed that a patient-specific pain management plan is on file for the patient AND

d. ONE of the following:

1. Patient's medication history includes use of an immediate-acting opioid OR

2. Patient has an intolerance or hypersensitivity to an immediate-acting opioid OR

3. Patient has an FDA labeled contraindication to an immediate-acting opioid AND

e. Prescriber has confirmed that the patient is not diverting controlled substances, according to the patient's records in the state's prescription drug monitoring program (PDMP), if applicable AND

f. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Opioids ER PA – Morphine

**Drug Name(s)**

Morphine Sulfate Er

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of chronic cancer pain due to an active malignancy OR

B. Patient is undergoing treatment of chronic non-cancer pain AND ONE of the following:

i. There is evidence of a claim that indicates the patient has been treated with the requested agent within the past 90 days OR

ii. Prescriber states the patient has been treated with the requested agent within the past 90 days OR

iii. ALL of the following:

a. Prescriber has provided documentation of a formal, consultative evaluation including BOTH of the following:

1. Diagnosis AND

2. A complete medical history which includes previous and current pharmacological and non-pharmacological therapy AND

b. The requested agent is NOT prescribed as an as-needed (prn) analgesic AND

c. Prescriber has confirmed that a patient-specific pain management plan is on file for the patient AND

d. ONE of the following:

1. Patient's medication history includes use of an immediate-acting opioid OR

2. Patient has an intolerance or hypersensitivity to an immediate-acting opioid OR

3. Patient has an FDA labeled contraindication to an immediate-acting opioid AND

e. Prescriber has confirmed that the patient is not diverting controlled substances, according to the patient's records in the state's prescription drug monitoring program (PDMP), if applicable AND

f. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Oral Immunotherapy Agents PA – Oralair

**Drug Name(s)**

Oralair

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of allergic rhinitis, with or without conjunctivitis AND
2. Patient's diagnosis is confirmed with ONE of the following:
  - a. Positive skin test to ONE of the pollen extracts included in the requested agent OR
  - b. IgE specific antibodies to ONE of the extracts included in the requested agent: Sweet vernal, orchard, perennial rye, Timothy, or Kentucky blue grass AND
3. ONE of the following:
  - a. Patient has tried and had an inadequate response to TWO standard allergy medications, one of which was an intranasal corticosteroid OR
  - b. Patient has an intolerance or hypersensitivity to TWO standard allergy medications, one of which was an intranasal corticosteroid OR
  - c. Patient has an FDA labeled contraindication to TWO standard allergy medications, one of which was an intranasal corticosteroid AND
4. Patient will NOT be using the requested agent in combination with a subcutaneous injectable immunotherapy agent AND
5. The requested agent will be started, or has already been started, 3 to 4 months before the expected onset of the applicable pollen season AND
6. The first dose is given in the clinic/hospital under direct supervision from the provider for a period of at least 30 minutes AND
7. Patient has been prescribed epinephrine auto-injector for at home emergency use

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, immunologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Standard allergy medications:

Oral antihistamines, oral corticosteroids, intranasal corticosteroids, intranasal antihistamines, or leukotriene inhibitors

**Prior Authorization Group Description:**

Orkambi PA

**Drug Name(s)**

Orkambi

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of cystic fibrosis AND
2. ONE of the following:
  - A. Patient has the presence of the F508del mutation on both alleles (homozygous) of the CFTR gene confirmed by genetic testing OR
  - B. Patient has another CFTR gene mutation(s) that is responsive to the requested agent AND
3. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of cystic fibrosis AND
3. Patient has had improvement or stabilization with the requested agent [e.g., improvement in FEV1 from baseline, increase in weight/BMI, improvement from baseline Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain score, improvements in respiratory symptoms (cough, sputum production, and difficulty breathing), and/or reduced number of pulmonary exacerbations] AND
4. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cystic fibrosis, pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Panretin PA

**Drug Name(s)**

Panretin

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. ONE of the following:

- a. Patient has a diagnosis of cutaneous lesions associated with AIDS-related Kaposi's sarcoma (KS) OR
- b. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

2. ONE of the following:

a. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR

b. Prescriber states the patient has been treated with the requested agent OR

c. ALL of the following:

i. ONE of the following:

1. BOTH of the following:

- a. Patient has a diagnosis of cutaneous lesions associated with AIDS-related Kaposi's sarcoma (KS) AND
- b. Patient does NOT require systemic anti-Kaposi's sarcoma therapy OR

2. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, dermatologist, infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis AND

iii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Pegylated Interferon PA

**Drug Name(s)**

Pegasys

Pegasys Proclick

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of chronic hepatitis B AND BOTH of the following:

i. The chronic hepatitis B infection has been confirmed by serological markers AND

ii. Patient has NOT been administered the requested agent for more than 48 weeks for the treatment of chronic hepatitis B OR

B. BOTH of the following:

i. Patient has a diagnosis of chronic hepatitis C confirmed by serological markers AND

ii. The requested agent will be used in a treatment regimen and length of therapy that is supported in FDA approved labeling or AASLD/IDSA guidelines for the patient's diagnosis and genotype OR

C. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months for all other diagnoses. For hep B, hep C see Other Criteria

**Other Criteria:**

No prior peginterferon alfa use, approve 48 weeks for hepatitis B virus infection. Prior peginterferon alfa use, approve remainder of 48 weeks of total therapy for hepatitis B virus infection

Duration of therapy for hepatitis C: Based on FDA approved labeling or AASLD/IDSA guideline supported

**Prior Authorization Group Description:**

Posaconazole PA

**Drug Name(s)**

Posaconazole

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindication(s) to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of oropharyngeal candidiasis AND patient has tried fluconazole or an alternative antifungal agent OR patient has a documented intolerance, FDA labeled contraindication(s), or hypersensitivity to fluconazole or an alternative antifungal agent OR
- B. The requested agent is being prescribed for prophylaxis of invasive Aspergillus or Candida AND patient is severely immunocompromised, such as a hematopoietic stem cell transplant [HSCT] recipient, or hematologic malignancy with prolonged neutropenia from chemotherapy, or is a high-risk solid organ (lung, heart-lung, liver, pancreas, small bowel) transplant patient, or long term use of high dose corticosteroids (greater than 1 mg/kg/day of prednisone or equivalent) OR
- C. Patient has a diagnosis of invasive Aspergillus AND patient has tried an alternative antifungal agent OR patient has a documented intolerance, FDA labeled contraindication(s), or hypersensitivity to an alternative antifungal agent OR
- D. Patient has another indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

One month for oropharyngeal candidiasis, 6 months for all other indications

**Other Criteria:**

Criteria for renewal approval require BOTH of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. ONE of the following:
  - A. The requested agent is being prescribed for prophylaxis of invasive Aspergillus or Candida and patient continues to be severely immunocompromised, such as a hematopoietic stem cell transplant [HSCT] recipient, or hematologic malignancy with prolonged neutropenia from chemotherapy, or is a high-risk solid organ (lung, heart-lung, liver, pancreas, small bowel) transplant patient, or long term use of high dose corticosteroids (greater than 1 mg/kg/day of prednisone or equivalent) OR
  - B. Patient has a diagnosis of invasive Aspergillus AND patient has continued indicators of active disease (e.g., continued radiologic findings, positive cultures, positive serum galactomannan assay for Aspergillus) OR
  - C. BOTH of the following:
    - i. Patient has another indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient has shown clinical benefit with the requested agent

**Prior Authorization Group Description:**

Prolia PA

**Drug Name(s)**

Prolia

**Indications:**

All FDA-Approved Indications, Some Medically-Accepted Indications.

**Off-Label Uses:**

osteopenia (osteoporosis prophylaxis)

**Exclusion Criteria:**

FDA labeled contraindication(s) to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of:

1. ONE of:

A. Patient (pt) is a male or a postmenopausal female with a diagnosis of osteoporosis AND BOTH of:

i. Pt's diagnosis was confirmed by ONE of:

1. A fragility fracture in the hip or spine OR

2. A T-score of -2.5 or lower OR

3. A T-score of -1.0 to -2.5 AND ONE of:

a. a FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR

b. a FRAX 10-year probability of hip fracture of 3% or greater AND

ii. ONE of:

1. Pt is at a very high fracture risk as defined by ONE of:

a. Pt had a recent fracture (within the past 12 months) OR

b. Pt had fractures while on FDA approved osteoporosis therapy OR

c. Pt has had multiple fractures OR

d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR

e. Pt has a very low T-score (less than -3.0) OR

f. Pt is at high risk for falls or has a history of injurious falls OR

g. Pt has a very high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 30%, hip fracture greater than 4.5%) or by other validated fracture risk algorithm OR

2. ONE of:

a. Pt's medication history includes use of a bisphosphonate OR

b. Pt has a documented intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR

B. Pt is requesting the agent for osteopenia (osteoporosis prophylaxis) AND ALL of:

i. ONE of:

1. Pt is a male 50 years of age and over OR

2. Pt is a postmenopausal female AND

ii. Pt has a T-score between -1.0 to -2.50 AND

iii. ONE of:

1. 10-year probability of a hip fracture 3% and greater per FRAX OR

2. 10-year probability of a major OP-related fracture 20% and greater per FRAX AND

iv. ONE of:

1. Pt's medication history includes use of a bisphosphonate OR



2. Pt has a documented intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR

Criteria continues: See Other Criteria

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

C. Pt is a female with a diagnosis of breast cancer who is receiving aromatase inhibitor therapy AND ONE of:

- i. Pt's medication history includes use of a bisphosphonate OR
- ii. Pt has a documented intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR

D. Pt is a male with a diagnosis of prostate cancer receiving androgen deprivation therapy (ADT) AND ONE of:

- i. Pt's medication history includes use of a bisphosphonate OR
- ii. Pt has a documented intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR

E. Pt has a diagnosis of glucocorticoid-induced osteoporosis AND ALL of:

- i. Pt is either initiating or continuing systemic glucocorticoids in a daily dose equivalent to 7.5 mg or greater of prednisone AND
- ii. Pt is expected to remain on glucocorticoids for at least 6 months AND
- iii. Pt's diagnosis was confirmed by ONE of:

- 1. A fragility fracture in the hip or spine OR
- 2. A T-score of -2.5 or lower OR
- 3. A T-score of -1.0 to -2.5 AND ONE of:
  - a. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
  - b. A FRAX 10-year probability of hip fracture of 3% or greater AND

iv. ONE of:

- 1. Pt is at a very high fracture risk as defined by ONE of:
  - a. Pt had a recent fracture (within the past 12 months) OR
  - b. Pt had fractures while on FDA approved osteoporosis therapy OR
  - c. Pt has had multiple fractures OR
  - d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
  - e. Pt has a very low T-score (less than -3.0) OR
  - f. Pt is at high risk for falls or has a history of injurious falls OR
  - g. Pt has a very high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 30%, hip fracture greater than 4.5%) or by other validated fracture risk algorithm OR

2. ONE of:

- a. Pt's medication history includes use of a bisphosphonate OR
- b. Pt has a documented intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate AND

2. ONE of:

- A. Pt has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
  - B. Pt has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
  - C. Prescriber has indicated that the pt is not at risk for hypocalcemia (not including risk associated with the requested agent) AND
3. ONE of:
- D. Pt is not currently being treated with Evenity (romosozumab-aqqg), teriparatide, Tymlos (abaloparatide), Xgeva (denosumab), bisphosphonate, or SERM therapy within the past 90 days OR
  - E. Pt is currently being treated with Evenity (romosozumab-aqqg) and will discontinue teriparatide, Tymlos (abaloparatide), Xgeva (denosumab), bisphosphonate, or SERM therapy prior to initiating therapy with the requested agent AND
4. The requested dose is within the FDA labeled dosing for the requested indication

**Prior Authorization Group Description:**

Promacta PA

**Drug Name(s)**

Promacta

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ONE of the following:

1. Patient has a diagnosis of persistent or chronic immune (idiopathic) thrombocytopenia (ITP) AND ONE of the following:

A. Patient has tried and had an insufficient response to a corticosteroid or immunoglobulin (IVIg or anti-D) OR

B. Patient has an intolerance or hypersensitivity to a corticosteroid or immunoglobulin (IVIg or anti-D) OR

C. Patient has an FDA labeled contraindication to a corticosteroid or immunoglobulin (IVIg or anti-D) OR

D. Patient has had an insufficient response to a splenectomy OR

2. Patient has a diagnosis of hepatitis C associated thrombocytopenia AND ONE of the following:

A. Patient's platelet count is less than 75 x10<sup>9</sup>/L AND the intent is to increase platelet counts sufficiently to initiate pegylated interferon therapy OR

B. Patient is on concurrent therapy with a pegylated interferon and ribavirin AND is at risk for discontinuing hepatitis C therapy due to thrombocytopenia OR

3. Patient has a diagnosis of severe aplastic anemia (SAA) AND ALL of the following:

A. Patient has at least 2 of the following blood criteria:

i. Neutrophils less than 0.5 X 10<sup>9</sup>/L OR

ii. Platelets less than 20 X 10<sup>9</sup>/L OR

iii. Reticulocytes less than 1% corrected [percentage of actual hematocrit (Hct) to normal Hct] or reticulocyte count less than 20 X 10<sup>9</sup>/L AND

B. Patient has at least 1 of the following marrow criteria:

i. Severe hypocellularity is less than 25% OR

ii. Moderate hypocellularity is 25-50% with hematopoietic cells representing less than 30% of residual cells AND

C. ONE of the following:

i. BOTH of the following:

1. Patient will be using the requested agent as first-line treatment AND

2. Patient will use the requested agent in combination with standard immunosuppressive therapy [i.e., antithymocyte globulin (ATG) AND cyclosporine] OR

Initial criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Initial 6 mo ITP & First-line SAA, 48 wks HCV, 16 wks other SAA Renewal 12 mo ITP & SAA, 48 wks HCV

**Other Criteria:**

ii. ONE of the following:

1. Patient has tried and had an insufficient response to BOTH antithymocyte globulin (ATG) AND cyclosporine therapy OR
2. Patient has an intolerance or hypersensitivity to BOTH ATG and cyclosporine OR
3. Patient has an FDA labeled contraindication to BOTH ATG and cyclosporine

Criteria for renewal approval require BOTH of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of persistent or chronic immune (idiopathic) thrombocytopenia (ITP) AND ONE of the following:

i. Patient's platelet count is  $50 \times 10^9/L$  or greater OR

ii. Patient's platelet count has increased sufficiently to avoid clinically significant bleeding OR

B. Patient has a diagnosis of hepatitis C associated thrombocytopenia AND BOTH of the following:

i. ONE of the following:

1. Patient will be initiating hepatitis C therapy with pegylated interferon and ribavirin OR

2. Patient will be maintaining hepatitis C therapy with pegylated interferon and ribavirin at the same time as the requested agent AND

ii. ONE of the following:

1. Patient's platelet count is  $90 \times 10^9/L$  or greater OR

2. Patient's platelet count has increased sufficiently to initiate or maintain pegylated interferon based therapy for the treatment of hepatitis C OR

C. Patient has a diagnosis of severe aplastic anemia (SAA) AND ONE of the following:

i. BOTH of the following:

1. Patient is using the requested agent in combination with standard immunosuppressive therapy [i.e., antithymocyte globulin (ATG) AND cyclosporine] for the first-line treatment of severe aplastic anemia AND

2. Patient has had a response by 6 months defined as meeting TWO of the following values:

a. An absolute neutrophil count (ANC) greater than 500/mcL OR

b. Platelet count greater than  $20 \times 10^9/L$  OR

c. Reticulocyte count greater than 60,000/mcL

OR

ii. Patient is not using the requested agent in combination with standard immunosuppressive therapy AND has had a hematological response by week 16 defined as ONE of the following:

1. Platelet count increased at least  $20 \times 10^9/L$  above baseline OR

2. Stable platelet counts with transfusion independence for a minimum of 8 weeks OR

3. Hemoglobin increase by greater than 1.5 g/dL OR

4. Reduction in 4 units or greater of red blood cell (RBC) transfusions for 8 consecutive weeks

OR

5. An absolute neutrophil count (ANC) increase of 100% OR

6. An absolute neutrophil count (ANC) increase greater than  $0.5 \times 10^9/L$

**Prior Authorization Group Description:**

Pulmonary Hypertension PA – Adempas

**Drug Name(s)**

Adempas

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

a. There is evidence of a claim that the patient has been treated with the requested agent within the past 90 days OR

b. Prescriber states the patient has been treated with the requested agent AND is at risk if therapy is changed AND

ii. Patient has an FDA labeled indication for the requested agent OR

B. Patient has a diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group 4, as determined by a ventilation-perfusion scan and a confirmatory selective pulmonary angiography AND ALL of the following:

i. ONE of the following:

a. Patient is NOT a candidate for surgery OR

b. Patient has had pulmonary endarterectomy AND has persistent or recurrent disease AND

ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND

iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND

iv. Patient has a pulmonary vascular resistance greater than or equal to 3 Wood units OR

C. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

i. Patient's World Health Organization (WHO) functional class is II or greater AND

ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND

iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND

iv. Patient has a pulmonary vascular resistance greater than or equal to 3 Wood units AND

v. ONE of the following:

a. The requested agent will be utilized as monotherapy OR

b. The requested agent will be utilized for add-on therapy to existing monotherapy (dual therapy), AND BOTH of the following:

1. Patient has unacceptable or deteriorating clinical status despite established pharmacotherapy AND

2. The requested agent is in a different therapeutic class OR

Initial criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

c. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy), AND ALL of the following:

1. ONE of the following:

i. A prostanoid has been started as one of the agents in the triple therapy OR

ii. Patient has an intolerance or hypersensitivity to a prostanoid OR

iii. Patient has an FDA labeled contraindication to a prostanoid AND

2. Patient has unacceptable or deteriorating clinical status despite established pharmacotherapy AND

3. All three agents in the triple therapy are from a different therapeutic class

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. Patient has an FDA labeled indication for the requested agent AND

3. Patient has had clinical benefit with the requested agent

**Prior Authorization Group Description:**

Pulmonary Hypertension PA – Ambrisentan

**Drug Name(s)**

Ambrisentan

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

a. There is evidence of a claim that the patient has been treated with the requested agent within the past 90 days OR

b. Prescriber states the patient has been treated with the requested agent AND is at risk if therapy is changed AND

ii. Patient has an FDA labeled indication for the requested agent OR

B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

i. Patient's World Health Organization (WHO) functional class is II or greater AND

ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND

iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND

iv. Patient has a pulmonary vascular resistance greater than or equal to 3 Wood units AND

v. ONE of the following:

a. The requested agent will be utilized as monotherapy OR

b. The request is for ambrisentan for use in combination with Adcirca or Alyq (tadalafil) for dual therapy ONLY OR

c. The requested agent will be utilized for add-on therapy to existing monotherapy [dual therapy, except for dual therapy requests for ambrisentan with Adcirca or Alyq (tadalafil)], AND BOTH of the following:

1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND

2. The requested agent is in a different therapeutic class OR

Initial criteria continues: see Other Criteria

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

d. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy), AND ALL of the following:

1. ONE of the following:

- i. A prostanoid has been started as one of the agents in the triple therapy OR
  - ii. Patient has an intolerance or hypersensitivity to a prostanoid OR
  - iii. Patient has an FDA labeled contraindication to a prostanoid AND
- 2. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
  - 3. All three agents in the triple therapy are from a different therapeutic class

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has an FDA labeled indication for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent



**Prior Authorization Group Description:**

Pulmonary Hypertension PA – Opsumit

**Drug Name(s)**

Opsumit

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

a. There is evidence of a claim that the patient has been treated with the requested agent within the past 90 days OR

b. Prescriber states the patient has been treated with the requested agent AND is at risk if therapy is changed AND

ii. Patient has an FDA labeled indication for the requested agent OR

B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

i. Patient's World Health Organization (WHO) functional class is II or greater AND

ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND

iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND

iv. Patient has a pulmonary vascular resistance greater than or equal to 3 Wood units AND

v. ONE of the following:

a. The requested agent will be utilized as monotherapy OR

b. The requested agent will be utilized for add-on therapy to existing monotherapy [dual therapy], AND BOTH of the following:

1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND

2. The requested agent is in a different therapeutic class OR

c. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy), AND ALL of the following:

1. ONE of the following:

i. A prostanoid has been started as one of the agents in the triple therapy OR

ii. The patient has an intolerance or hypersensitivity to a prostanoid OR

iii. Patient has an FDA labeled contraindication to a prostanoid AND

2. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND

3. All three agents in the triple therapy are from a different therapeutic class

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent

**Prior Authorization Group Description:**

Pulmonary Hypertension PA – Sildenafil

**Drug Name(s)**

Sildenafil Citrate

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

Concurrently taking another phosphodiesterase type 5 (PDE-5) inhibitor [tadalafil (Adcirca, Alyq or Cialis) or sildenafil (Revatio or Viagra)] with the requested agent AND FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

a. There is evidence of a claim that the patient has been treated with the requested agent within the past 90 days OR

b. Prescriber states the patient has been treated with the requested agent AND is at risk if therapy is changed AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

i. Patient's World Health Organization (WHO) functional class is II or greater AND

ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND

iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND

iv. Patient has a pulmonary vascular resistance greater than or equal to 3 Wood units AND

v. ONE of the following:

a. The requested agent will be utilized as monotherapy OR

b. The requested agent will be utilized for add-on therapy to existing monotherapy [dual therapy], AND BOTH of the following:

1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND

2. The requested agent is in a different therapeutic class OR

Initial criteria continues: see Other Criteria

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

c. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy) AND ALL of the following:

1. ONE of the following:
  - i. A prostanoid has been started as one of the agents in the triple therapy OR
  - ii. The patient has an intolerance or hypersensitivity to a prostanoid OR
  - iii. Patient has an FDA labeled contraindication to a prostanoid AND
2. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
3. All three agents in the triple therapy are from a different therapeutic class OR
- C. Patient has an indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
3. Patient has had clinical benefit with the requested agent

**Prior Authorization Group Description:**

Repatha PA

**Drug Name(s)**

Repatha

Repatha Pushtronex System

Repatha Sureclick

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has ONE of the following:

A. A diagnosis of heterozygous familial hypercholesterolemia (HeFH) AND ONE of the following:

i. Genetic confirmation of one mutant allele at the LDLR, Apo-B, PCSK9, or 1/LDLRAP1 gene OR

ii. History of LDL-C greater than 190 mg/dL (greater than 4.9 mmol/L) (pretreatment) OR

iii. Patient has clinical manifestations of HeFH (e.g., cutaneous xanthomas, tendon xanthomas, arcus cornea, tuberous xanthoma, or xanthelasma) OR

iv. Patient has “definite” or “possible” familial hypercholesterolemia as defined by the Simon Broome criteria OR

v. Patient has a Dutch Lipid Clinic Network criteria score of greater than 5 OR

vi. Patient has a treated low-density lipoprotein cholesterol (LDL-C) level 100 mg/dL or greater after treatment with antihyperlipidemic agents but prior to PCSK9 inhibitor therapy OR

B. A diagnosis of homozygous familial hypercholesterolemia (HoFH) AND ONE of the following:

i. Genetic confirmation of two mutant alleles at the LDLR, Apo-B, PCSK9, or LDLRAP1 gene OR

ii. History of untreated LDL-C greater than 500 mg/dL (greater than 13 mmol/L) or treated LDL-C 300 mg/dL or greater (7.76 mmol/L or greater) OR

iii. Patient has clinical manifestations of HoFH (e.g., cutaneous xanthomas, tendon xanthomas, arcus cornea, tuberous xanthomas, or xanthelasma) OR

C. A diagnosis of established cardiovascular disease [angina pectoris, coronary heart disease, myocardial infarction, transient ischemic attacks, cerebrovascular disease (CeVD) or peripheral vascular disease (PVD) or after coronary revascularization or carotid endarterectomy] AND the requested agent will be used to reduce the risk of myocardial infarction, stroke, and coronary revascularization OR

D. A diagnosis of primary hyperlipidemia (not associated with HeFH, HoFH, or established cardiovascular disease) OR

Initial criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:**

The agent was prescribed by, or in consultation with, a cardiologist, an endocrinologist, and/or a physician who focuses in the treatment of cardiovascular (CV) risk management and/or lipid disorders

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

E. Patient has another indication that is supported in CMS approved compendia for the requested agent AND

2. ONE of the following:

A. Patient has tried and had an inadequate response to a high-intensity statin (i.e., rosuvastatin 20-40 mg or atorvastatin 40-80 mg) OR

B. Patient has an intolerance\* to TWO different statins (\*intolerance is defined as inability to tolerate the lowest FDA approved starting dose of a statin) OR

C. Patient has an FDA labeled contraindication to a statin AND

3. Patient will NOT be using the requested agent in combination with another PCSK9 agent

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND

3. Patient has had clinical benefit with the requested agent AND

4. Patient will NOT be using the requested agent in combination with another PCSK9 agent

**Prior Authorization Group Description:**

Roflumilast PA

**Drug Name(s)**

Daliresp

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. Patient has tried and had an inadequate response to an agent from two of the following categories:
    - i. long-acting beta-2 agonist (LABA) [e.g., salmeterol]
    - ii. long-acting muscarinic antagonist/anticholinergic (LAMA) [e.g., umeclidinium]
    - iii. inhaled corticosteroid (ICS) [e.g., fluticasone] OR
  - B. Patient has an intolerance or hypersensitivity to an agent from two of the following categories:
    - i. long-acting beta-2 agonist (LABA) [e.g., salmeterol]
    - ii. long-acting muscarinic antagonist/anticholinergic (LAMA) [e.g., umeclidinium]
    - iii. inhaled corticosteroid (ICS) [e.g., fluticasone] OR
  - C. Patient has an FDA labeled contraindication to an agent from two of the following categories:
    - i. long-acting beta-2 agonist (LABA) [e.g., salmeterol]
    - ii. long-acting muscarinic antagonist/anticholinergic (LAMA) [e.g., umeclidinium]
    - iii. inhaled corticosteroid (ICS) [e.g., fluticasone]

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Sapropterin PA

**Drug Name(s)**

Sapropterin Dihydrochloride

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of phenylketonuria (PKU) AND
2. Prescriber has submitted a baseline blood Phe level measured prior to initiation of therapy with the requested agent, which is above the recommended levels indicated for the patient's age range or condition AND
3. ONE of the following:
  - a. Patient is NOT currently being treated with Palynziq (pegvaliase-pqpz) OR
  - b. Patient is currently being treated with Palynziq (pegvaliase-pqpz), AND will discontinue prior to initiating Kuvan (sapropterin) AND
4. The requested dose is within the FDA labeled dose for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of phenylketonuria (PKU) AND
3. ONE of the following:
  - a. Patient's blood Phe levels are being maintained within the acceptable range OR
  - b. Patient has had a decrease in blood Phe level from baseline AND
4. ONE of the following:
  - a. Patient is NOT currently being treated with Palynziq (pegvaliase-pqpz) OR
  - b. Patient is currently being treated with Palynziq (pegvaliase-pqpz), AND will discontinue prior to continuing Kuvan (sapropterin) AND
5. The requested dose is within the FDA labeled dose for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist with knowledge and expertise in metabolic diseases or genetic diseases or has consulted with a specialist in metabolic or genetic diseases

**Coverage Duration:**

Initial: 2 months if dose is 5 to less than 20 mg/kg/day, 1 month if 20 mg/kg/day Renewal: 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Self - Administered Oncology PA

**Drug Name(s)**

Abiraterone Acetate  
Alecensa  
Alunbrig  
Ayvakit  
Balversa  
Besremi  
Bexarotene  
Bosulif  
Braftovi  
Brukinsa  
Cabometyx  
Calquence  
Caprelsa  
Cometriq  
Copiktra  
Cotellic  
Daurismo  
Erivedge  
Erleada  
Erlotinib Hydrochloride  
Everolimus  
Everolimus Oral Suspension Tablet  
Exkivity  
Farydak  
Fotivda  
Gavreto  
Gilotrif  
Ibrance  
Iclusig  
Idhifa  
Imatinib Mesylate  
Imbruvica  
Inlyta  
Inqovi  
Inrebic  
Iressa  
Jakafi  
Kisqali  
Kisqali Femara 200 Dose  
Kisqali Femara 400 Dose  
Kisqali Femara 600 Dose

Koselugo  
Lapatinib Ditosylate  
Lenalidomide  
Lenvima 10 Mg Daily Dose  
Lenvima 12Mg Daily Dose  
Lenvima 14 Mg Daily Dose  
Lenvima 18 Mg Daily Dose  
Lenvima 20 Mg Daily Dose  
Lenvima 24 Mg Daily Dose  
Lenvima 4 Mg Daily Dose  
Lenvima 8 Mg Daily Dose  
Lonsurf  
Lorbrena  
Lumakras  
Lynparza  
Matulane  
Mekinist  
Mektovi  
Nerlynx  
Nexavar  
Ninlaro  
Nubeqa  
Odomzo  
Onureg  
Orgovyx  
Pemazyre  
Piqray 200Mg Daily Dose  
Piqray 250Mg Daily Dose  
Piqray 300Mg Daily Dose  
Pomalyst  
Qinlock  
Retevmo  
Revlimid  
Rozlytrek  
Rubraca  
Rydapt  
Scemblix  
Sorafenib  
Sprycel  
Stivarga  
Sunitinib Malate  
Tabrecta  
Tafinlar  
Tagrisso

Talzenna  
Tasigna  
Tazverik  
Tepmetko  
Thalomid  
Tibsovo  
Tretinoin Capsule  
Truseltiq  
Tukysa  
Turalio  
Venclexta  
Venclexta Starting Pack  
Verzenio  
Vitrakvi  
Vizimpro  
Vonjo  
Votrient  
Welireg  
Xalkori  
Xospata  
Xpovio  
Xpovio 100 Mg Once Weekly  
Xpovio 40 Mg Once Weekly  
Xpovio 40 Mg Twice Weekly  
Xpovio 60 Mg Once Weekly  
Xpovio 60 Mg Twice Weekly  
Xpovio 80 Mg Once Weekly  
Xpovio 80 Mg Twice Weekly  
Xtandi  
Zejula  
Zelboraf  
Zolinza  
Zydelig  
Zykadia

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. ONE of the following:

A. Patient has an FDA labeled indication for the requested agent OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

2. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient has been treated with the requested agent OR
  - C. ALL of the following:
    - i. Genetic testing has been completed, if required, for therapy with the requested agent and results indicate the requested agent is appropriate AND
    - ii. Patient does NOT have any FDA labeled contraindications to the requested agent AND
    - iii. ONE of the following:
      - a. Patient has tried appropriate FDA-labeled or compendia-supported therapy that are indicated in NCCN guidelines as first-line therapy OR
      - b. Patient has an intolerance or hypersensitivity to the first-line therapy for the requested indication OR
      - c. Patient has an FDA labeled contraindication to the first-line therapy for the requested indication AND
      - iv. Patient does NOT have any FDA labeled limitations of use that is not otherwise supported in NCCN guidelines AND
      - v. ONE of the following:
        - a. The requested agent is not Kisqali, Kisqali/Femara, or Verzenio OR
        - b. The requested agent is Kisqali, Kisqali/Femara, or Verzenio AND ONE of the following:
          1. Patient's medication history indicates use of Ibrance for the requested indication (if applicable) OR
          2. Patient has an intolerance or hypersensitivity to Ibrance OR
          3. Patient has an FDA labeled contraindication to Ibrance OR
          4. CMS approved compendia do not support the use of Ibrance for the requested indication OR
          5. Prescriber has provided information in support of use of Kisqali, Kisqali/Femara, or Verzenio over Ibrance for the requested indication AND

Criteria continues: see Other Criteria

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- vi. ONE of the following:
  - a. The requested agent is not Bosulif or Tassigna OR
  - b. The requested agent is Bosulif or Tassigna AND ONE of the following:
    1. Patient's medication history indicates use of imatinib OR Sprycel for the requested indication (if applicable) OR
    2. Patient has an intolerance or hypersensitivity to imatinib OR Sprycel OR
    3. Patient has an FDA labeled contraindication to imatinib OR Sprycel OR
    4. CMS approved compendia does not support the use of imatinib OR Sprycel for the requested indication OR
    5. Prescriber has provided information in support of use of Bosulif or Tassigna over imatinib OR Sprycel for the requested indication

**Prior Authorization Group Description:**

Signifor PA

**Drug Name(s)**

Signifor

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

Severe hepatic impairment (i.e., Child Pugh C)

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of Cushing's disease (CD) AND ONE of the following:

i. Patient had an inadequate response to pituitary surgical resection OR

ii. Patient is NOT a candidate for pituitary surgical resection OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require BOTH of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of Cushing's disease (CD) AND BOTH of the following:

i. Patient has a urinary free cortisol level less than or equal to the upper limit of normal AND

ii. Patient has shown improvement in at least ONE of the following clinical signs and symptoms:

1. Fasting plasma glucose OR

2. Hemoglobin A1c OR

3. Hypertension OR

4. Weight OR

B. BOTH of the following:

i. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient has shown clinical benefit with the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Initial approval: 6 months for CD, 12 months for all other diagnoses, Renewal approval: 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Sivextro PA

**Drug Name(s)**

Sivextro

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has ONE of the following:

a. BOTH of the following:

i. A documented acute bacterial skin and skin structure infection (ABSSSI) defined as a bacterial infection of the skin with a lesion size area of at least 75 cm<sup>2</sup> (lesion size measured by the area of redness, edema, or induration) AND

ii. The infection is due to *Staphylococcus aureus*, *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus anginosus*, *Streptococcus intermedius*, *Streptococcus constellatus*, or *Enterococcus faecalis* OR

b. Another indication that is supported in CMS approved compendia for the requested agent AND

2. ONE of the following:

a. The requested agent is prescribed by an infectious disease specialist or the prescriber has consulted with an infectious disease specialist on treatment of this patient OR

b. The requested agent is NOT prescribed by an infectious disease specialist or the prescriber has NOT consulted with an infectious disease specialist on treatment of this patient AND ONE of the following:

i. There is documentation of resistance to at least two of the following: beta lactams, macrolides, clindamycin, tetracycline, or co-trimoxazole at the site of infection OR the patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to at least two of the following: beta lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole OR

ii. There is documentation of resistance to vancomycin at the site of infection OR the patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to vancomycin AND

3. ONE of the following:

a. Patient is NOT currently being treated for the same infection with linezolid OR

b. The current treatment with linezolid for the same infection will be discontinued before starting therapy with the requested agent AND

4. The requested dose is within the FDA labeled or CMS approved compendia dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be 6 days for ABSSSI or 30 days for all other indications

**Other Criteria:**

**Prior Authorization Group Description:**

Somatostatin Analogs PA – Octreotide

**Drug Name(s)**

Octreotide Acetate

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. Patient has an FDA approved indication or an indication that is supported in CMS approved compendia for the requested agent AND ONE of the following:

i. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR

ii. Prescriber states the patient is currently being treated with the requested agent AND is at risk if therapy is changed OR

B. ONE of the following:

i. Patient has a diagnosis of acromegaly AND ONE of the following:

a. Patient is not a candidate for surgical resection or pituitary radiation therapy OR

b. The requested agent is for adjunctive therapy with pituitary radiation therapy OR

c. Patient had an inadequate response to surgery or pituitary radiation therapy as indicated by growth hormone levels or serum IGF-1 levels that are above the reference range OR

ii. Patient has severe diarrhea and/or flushing episodes associated with metastatic carcinoid tumors OR

iii. Patient has profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors OR

iv. Patient has a diagnosis of dumping syndrome AND ONE of the following:

a. Patient has tried and failed acarbose OR

b. Patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to acarbose OR

v. Patient has another indication that is supported in CMS approved compendia for the requested agent AND

2. The requested dose is within the FDA approved or CMS approved compendia dosing for the requested agent and indication

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be 6 months for initial, 12 months for renewal

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of acromegaly OR

- B. Patient has severe diarrhea and/or flushing episodes associated with metastatic carcinoid tumors OR
  - C. Patient has profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors OR
  - D. Patient has a diagnosis of dumping syndrome OR
  - E. Patient has another indication that is supported in CMS approved compendia for the requested agent AND
3. Patient has shown clinical benefit with the requested agent AND
  4. The requested dose is within the FDA approved or CMS approved compendia dosing for the requested agent and indication



**Prior Authorization Group Description:**

Somatostatin Analogs PA - Somatuline Depot

**Drug Name(s)**

Somatuline Depot

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for initial approval require ONE of the following:

1. Patient has an FDA approved indication or an indication that is supported in CMS approved compendia for the requested agent AND ONE of the following:

A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR

B. Prescriber states the patient is currently being treated with the requested agent OR

2. BOTH of the following:

A. ONE of the following:

i. Patient has a diagnosis of acromegaly AND ONE of the following:

a. Patient is not a candidate for surgical resection or pituitary radiation therapy OR

b. The requested agent is for adjunctive therapy with pituitary radiation therapy OR

c. Patient had an inadequate response to surgery or pituitary radiation therapy as indicated by growth hormone levels or serum IGF-1 levels that are above the reference range OR

ii. Patient has a diagnosis of gastroenteropancreatic neuroendocrine tumors AND BOTH of the following:

a. The tumors are well or moderately differentiated AND

b. ONE of the following:

1. The tumors are unresectable, locally advanced OR

2. Patient has metastatic disease OR

iii. Patient has a diagnosis of carcinoid syndrome OR

iv. Patient has another indication that is supported in CMS approved compendia for the requested agent AND

B. The requested dose is within the FDA approved or CMS approved compendia dosing for the requested agent and indication

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be 6 months for initial, 12 months for renewal

**Other Criteria:**

Criteria for renewal approval require ONE of the following:

1. Patient has an FDA approved indication or an indication that is supported in CMS approved compendia for the requested agent AND ONE of the following:

A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR

B. Prescriber states the patient is currently being treated with the requested agent OR

2. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND ALL of the following:

A. ONE of the following:

i. Patient has a diagnosis of acromegaly OR

ii. Patient has a diagnosis of metastatic OR unresectable, locally advanced, well or moderately differentiated gastroenteropancreatic neuroendocrine tumors OR

iii. Patient has a diagnosis of carcinoid syndrome OR

iv. Patient has another indication that is supported in CMS approved compendia for the requested agent AND

B. Patient has shown clinical benefit with the requested agent AND

C. The requested dose is within the FDA approved or CMS approved compendia dosing for the requested agent and indication

**Prior Authorization Group Description:**

Somatostatin Analogs PA – Somavert

**Drug Name(s)**

Somavert

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of acromegaly AND ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND is at risk if therapy is changed OR
  - C. BOTH of the following:
    - i. ONE of the following:
      - a. Patient is not a candidate for surgical resection or pituitary radiation therapy OR
      - b. The requested agent is for adjunctive therapy with pituitary radiation therapy OR
      - c. Patient had an inadequate response to surgery or pituitary radiation therapy as indicated by serum IGF-1 levels that are above the reference range AND
    - ii. ONE of the following:
      - a. Patient has tried and failed a prerequisite agent [octreotide or Somatuline Depot (lanreotide)] OR
      - b. Patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to a prerequisite agent AND
  2. The requested dose is within the FDA approved dosing for the requested agent and indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of acromegaly AND
3. Patient has shown clinical benefit with the requested agent AND
4. The requested dose is within the FDA approved dosing for the requested agent and indication

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be 6 months for initial, 12 months for renewal

**Other Criteria:**

**Prior Authorization Group Description:**

Spravato PA

**Drug Name(s)**

Spravato 56Mg Dose

Spravato 84Mg Dose

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. BOTH of the following:
  - a. ONE of the following:
    - i. Patient has a diagnosis of treatment-resistant depression (TRD) OR
    - ii. Patient has a diagnosis of major depressive disorder (MDD) with acute suicidal ideation or behavior AND
  - b. The requested agent will be used in combination with an oral antidepressant AND
2. ONE of the following:
  - a. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR
  - b. Prescriber states the patient has been treated with the requested agent OR
  - c. ALL of the following:
    - i. ONE of the following:
      1. BOTH of the following:
        - a. Patient has a diagnosis of treatment-resistant depression (TRD) AND
        - b. Patient has tried and had an inadequate response to at least two different oral antidepressants (e.g., SSRIs, SNRIs) OR
      2. Patient has a diagnosis of major depressive disorder (MDD) with acute suicidal ideation or behavior AND
    - ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., psychiatrist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis AND
    - iii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. BOTH of the following:
  - a. ONE of the following:
    - i. Patient has a diagnosis of treatment-resistant depression (TRD) OR

- ii. Patient has a diagnosis of major depressive disorder (MDD) with acute suicidal ideation or behavior AND
- b. The requested agent will be used in combination with an oral antidepressant AND
- 3. ONE of the following:
  - a. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR
  - b. Prescriber states the patient has been treated with the requested agent OR
  - c. ALL of the following:
    - i. Patient has had clinical benefit with the requested agent AND
    - ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., psychiatrist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis AND
    - iii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Prior Authorization Group Description:**

Strensiq PA

**Drug Name(s)**

Strensiq

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has ONE of the following diagnoses:
  - a. Perinatal or infantile-onset hypophosphatasia OR
  - b. Juvenile-onset hypophosphatasia AND
2. Patient has documentation (i.e., medical records) of clinical manifestations to support the diagnosis of hypophosphatasia at the age of onset prior to age 18 (e.g., vitamin B6-dependent seizures, skeletal abnormalities such as rachitic chest deformity leading to respiratory problems or bowed arms/legs, “failure to thrive”) AND
3. Patient has documentation (i.e., medical records) of radiographic imaging to support the diagnosis of hypophosphatasia at the age of onset prior to age 18 (e.g., infantile rickets, alveolar bone loss, craniosynostosis, fractures) AND
4. Patient has documentation (i.e., medical records) of confirmed mutation(s) in the ALPL gene that encodes the tissue non-specific isoenzyme of alkaline phosphatase (TNSALP)  
AND
5. Patient has documentation (i.e., medical records) of a measured total serum alkaline phosphatase (ALP) level that is below the normal lab reference range for age and sex AND
6. Patient has documentation (i.e., medical records) of ONE of the following:
  - a. Elevated urine concentration of phosphoethanolamine (PEA) OR
  - b. Elevated serum concentration of pyridoxal 5'-phosphate (PLP) in the absence of vitamin supplements within one week prior to the test OR
  - c. Elevated urinary inorganic pyrophosphate (PPi) AND
7. The requested dose is within the FDA labeled dosing (based on the patient’s weight) for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist (e.g., endocrinologist or geneticist with expertise in metabolic bone diseases) or the prescriber has consulted with a specialist

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan’s Prior Authorization criteria AND
2. Patient has ONE of the following diagnoses:
  - a. Perinatal or infantile-onset hypophosphatasia OR

- b. Juvenile-onset hypophosphatasia AND
- 3. There is documentation (i.e., medical records) that the patient has had a decrease in at least ONE of the following levels:
  - a. Urine concentration of phosphoethanolamine (PEA) OR
  - b. Serum concentration of pyridoxal 5'-phosphate (PLP) in the absence of vitamin supplements within one week prior to the test OR
  - c. Urinary inorganic pyrophosphate (PPi) AND
- 4. Patient has documentation (i.e., medical records) of clinical improvement and/or stabilization with the requested agent (e.g., improvement in respiratory status, growth, pain, radiographic findings, other symptoms associated with the disease) AND
- 5. The requested dose is within the FDA labeled dosing (based on the patient's weight) for the requested indication

**Prior Authorization Group Description:**

Substrate Reduction Therapy PA – Miglustat

**Drug Name(s)**

Miglustat

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of Gaucher disease type 1 (GD1) confirmed by ONE of the following:
  - A. A baseline glucocerebrosidase enzyme activity of less than or equal to 15% of mean normal in peripheral blood leukocytes, fibroblasts, or other nucleated cells OR
  - B. Confirmation of genetic mutation of GBA gene with two disease-causing alleles AND
2. ONE of the following:
  - A. Patient has tried and had an inadequate response to ONE enzyme replacement therapy (i.e., Cerezyme, Eleyso, Vpriv) OR
  - B. Patient has an intolerance or hypersensitivity to ONE enzyme replacement therapy (i.e., Cerezyme, Eleyso, Vpriv) OR
  - C. Patient has an FDA labeled contraindication to ONE enzyme replacement therapy (i.e., Cerezyme, Eleyso, Vpriv) AND
3. Prescriber has drawn baseline measurements of hemoglobin level, platelet count, liver volume, and spleen volume AND
4. Prior to any treatment for the intended diagnosis, the patient has had at least ONE of the following clinical presentations:
  - A. Anemia [defined as mean hemoglobin (Hb) level below the testing laboratory's lower limit of the normal range based on age and gender] OR
  - B. Thrombocytopenia (defined as platelet count of less than 100,000 per microliter) OR
  - C. Hepatomegaly OR
  - D. Splenomegaly OR
  - E. Growth failure (i.e., growth velocity is below the standard mean for age) OR
  - F. Evidence of bone disease with other causes ruled out

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Gaucher disease type 1 (GD1) AND
3. Patient has had improvements or stabilization with the requested agent as indicated by ONE of the following:
  - A. Spleen volume OR
  - B. Hemoglobin level OR
  - C. Liver volume OR
  - D. Platelet count OR
  - E. Growth OR



F. Bone pain or crisis

**Age Restriction:**

Approval will be for 12 months

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, geneticist, hematologist, specialist in metabolic diseases) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

**Other Criteria:**

**Prior Authorization Group Description:**

Symdeko PA

**Drug Name(s)**

Symdeko

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of cystic fibrosis AND
2. ONE of the following:
  - A. Patient has the presence of the F508del mutation on both alleles (homozygous) of the CFTR gene confirmed by genetic testing OR
  - B. Patient has ONE of the CFTR gene mutations or a mutation in the CFTR gene that is responsive based on in vitro data, as indicated in the FDA label, confirmed by genetic testing OR
  - C. Patient has another CFTR gene mutation(s) that is responsive to the requested agent AND
3. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of cystic fibrosis AND
3. Patient has had improvement or stabilization with the requested agent [e.g., improvement in FEV1 from baseline, increase in weight/BMI, improvement from baseline Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain score, improvements in respiratory symptoms (cough, sputum production, and difficulty breathing), and/or reduced number of pulmonary exacerbations] AND
4. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cystic fibrosis, pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Targretin Gel PA

**Drug Name(s)**

Bexarotene (Topical)

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

- A. Patient has a diagnosis of stage IA or IB cutaneous T-cell lymphoma (CTCL) with cutaneous lesions OR
- B. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

2. ONE of the following:

A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR

B. Prescriber states the patient is currently being treated with the requested agent OR

C. ALL of the following:

i. ONE of the following:

1. BOTH of the following:

a. Patient has a diagnosis of stage IA or IB cutaneous T-cell lymphoma (CTCL) with cutaneous lesions AND

b. ONE of the following:

i. Patient has refractory or persistent disease despite a previous treatment trial (a skin-directed therapy, e.g., topical corticosteroid, topical imiquimod) OR

ii. Patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to a previous treatment trial (a skin-directed therapy, e.g., topical corticosteroid, topical imiquimod) OR

2. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Prescriber is a specialist (e.g., dermatologist, oncologist) or the prescriber has consulted with a specialist AND

iii. Patient does NOT have any FDA labeled contraindication(s) to the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of stage IA or IB cutaneous T-cell lymphoma (CTCL) with cutaneous lesions OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

3. ONE of the following:

- A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
- B. Prescriber states the patient is currently being treated with the requested agent OR
- C. ALL of the following:
  - i. Patient has shown clinical benefit with the requested agent AND
  - ii. Prescriber is a specialist (e.g., dermatologist, oncologist) or the prescriber has consulted with a specialist AND
  - iii. Patient does NOT have any FDA labeled contraindication(s) to the requested agent

**Prior Authorization Group Description:**

Tetrabenazine PA

**Drug Name(s)**

Tetrabenazine

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. ONE of the following:

A. Patient has a diagnosis of chorea associated with Huntington's disease OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

2. If the patient has a current diagnosis of depression, the patient is being treated for depression AND

3. If the patient has a diagnosis of suicidal ideation and/or behavior, the patient must not be actively suicidal AND

4. Patient is NOT currently being treated with a monoamine oxidase inhibitor (MAOI) OR the patient's MAOI will be discontinued at least 14 days before starting therapy with the requested agent AND

5. Patient is NOT currently being treated with reserpine OR the patient's reserpine will be discontinued at least 20 days before starting therapy with the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Tobramycin neb PA

**Drug Name(s)**

Tobramycin

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of cystic fibrosis AND
2. Documentation has been provided that indicates the patient has a Pseudomonas aeruginosa respiratory infection AND
3. ONE of the following:
  - a. Patient is NOT currently (within the past 60 days) being treated with another inhaled antibiotic (e.g., inhaled aztreonam, inhaled tobramycin) OR
  - b. Patient is currently (within the past 60 days) being treated with another inhaled antibiotic (e.g., inhaled aztreonam, inhaled tobramycin) AND ONE of the following:
    - i. Prescriber has confirmed that the other inhaled antibiotic will be discontinued, and that therapy will be continued only with the requested agent OR
    - ii. Prescriber has provided information in support of another inhaled antibiotic therapy used concurrently with the requested agent

Drug is also subject to Part B versus Part D review.

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Topical NSAID PA – Voltaren

**Drug Name(s)**

Diclofenac Sodium

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

a. Patient has an FDA labeled indication for the requested agent OR

b. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

3 months for acute pain, 12 months for all other diagnoses

**Other Criteria:**

**Prior Authorization Group Description:**

Topical Retinoids PA – Tazarotene

**Drug Name(s)**

Tazarotene

Tazorac

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

Requested agent will NOT be used for cosmetic purposes

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

a. Patient has an FDA labeled indication for the requested agent OR

b. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Topical Retinoids PA – Tretinoin

**Drug Name(s)**

Avita

Tretinoin (Topical)

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

Requested agent will NOT be used for cosmetic purposes

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

a. Patient has an FDA labeled indication for the requested agent OR

b. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Trelstar PA

**Drug Name(s)**

Trelstar Mixject

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient has been treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient has been treated with the requested agent OR
  - C. BOTH of the following:
    - i. Patient is NOT currently being treated with the requested agent AND
    - ii. Patient does NOT have any FDA labeled contraindications to the requested agent AND
3. The requested dose is within the FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Trientine PA

**Drug Name(s)**

Clovique

Trientine Hydrochloride

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of Wilson's disease confirmed by ONE of the following:

A. Confirmation of genetic mutation of the ATP7B gene OR

B. Patient has TWO of the following:

i. Presence of hepatic abnormality (e.g., acute liver failure, cirrhosis, fatty liver)

ii. Presence of Kayser-Fleischer rings

iii. Serum ceruloplasmin level less than 20 mg/dL

iv. Basal urinary copper excretion greater than 40 mcg/24 hours or the testing laboratory's upper limit of normal

v. Hepatic parenchymal copper content greater than 40 mcg/g dry weight

vi. Presence of neurological symptoms (e.g., dystonia, hypertonia, rigidity with tremors, dysarthria, muscle spasms, dysphasia, polyneuropathy, dysautonomia) AND

2. ONE of the following:

A. Patient's medication history indicates use of penicillamine OR

B. Patient has an intolerance or hypersensitivity to penicillamine OR

C. Patient has an FDA labeled contraindication to penicillamine

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. Patient has a diagnosis of Wilson's disease AND

3. Patient has had clinical benefit with the requested agent as evidenced by ONE of the following:

A. Improvement and/or stabilization in hepatic abnormality OR

B. Reduction in Kayser-Fleischer rings OR

C. Improvement and/or stabilization in neurological symptoms (e.g., dystonia, hypertonia, rigidity with tremors, dysarthria, muscle spasms, dysphasia, polyneuropathy, dysautonomia) OR

D. Basal urinary copper excretion greater than 200 mcg/24 hours

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, hepatologist, neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Trikafta PA

**Drug Name(s)**

Trikafta

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of cystic fibrosis AND
2. ONE of the following:
  - A. Patient has the presence of the F508del mutation in at least ONE allele (heterozygous OR homozygous) of the CFTR gene confirmed by genetic testing OR
  - B. Patient has ONE of the CFTR gene mutations or a mutation in the CFTR gene that is responsive based on in vitro data, as indicated in the FDA label, confirmed by genetic testing OR
  - C. Patient has another CFTR gene mutation(s) that is responsive to the requested agent AND
3. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of cystic fibrosis AND
3. Patient has had improvement or stabilization with the requested agent [e.g., improvement in FEV1 from baseline, increase in weight/BMI, improvement from baseline Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain score, improvements in respiratory symptoms (cough, sputum production, and difficulty breathing), and/or reduced number of pulmonary exacerbations] AND
4. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cystic fibrosis, pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Tymlos PA

**Drug Name(s)**

Tymlos

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient is a postmenopausal female with a diagnosis of osteoporosis AND BOTH of the following:
  - A. Patient's diagnosis was confirmed by ONE of the following:
    - i. A fragility fracture in the hip or spine OR
    - ii. A T-score of -2.5 or lower OR
    - iii. A T-score of -1.0 to -2.5 AND ONE of the following:
      1. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
      2. A FRAX 10-year probability of hip fracture of 3% or greater AND
  - B. ONE of the following:
    - i. Patient is at a very high fracture risk as defined by ONE of the following:
      - a. Patient had a recent fracture (within the past 12 months) OR
      - b. Patient had fractures while on FDA approved osteoporosis therapy OR
      - c. Patient has had multiple fractures OR
      - d. Patient had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
      - e. Patient has a very low T-score (less than -3.0) OR
      - f. Patient is at high risk for falls or has a history of injurious falls OR
      - g. Patient has a very high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 30%, hip fracture greater than 4.5%) or by other validated fracture risk algorithm OR
    - ii. ONE of the following:
      - a. Patient has tried and had an inadequate response to a bisphosphonate OR
      - b. Patient has an intolerance or hypersensitivity to a bisphosphonate OR
      - c. Patient has an FDA labeled contraindication to a bisphosphonate AND
2. Patient will NOT be using the requested agent in combination with a bisphosphonate, SERM, Evenity (romosozumab-aqqg), Tymlos (abaloparatide), Prolia (denosumab), or Xgeva (denosumab) AND
3. The requested dose is within the FDA labeled dosing for the requested indication AND
4. The total cumulative duration of treatment with teriparatide and Tymlos (abaloparatide) has not exceeded 2 years

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

No prior Tymlos and/or teriparatide use approve 2 years, Prior use - see Other Criteria

**Other Criteria:**

Prior Tymlos and/or teriparatide use approve remainder of 2 years of total cumulative therapy

**Prior Authorization Group Description:**

Urea Cycle Disorders PA - Sodium Phenylbutyrate

**Drug Name(s)**

Sodium Phenylbutyrate

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindication(s) to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of ONE of the following:
  - a. Urea cycle disorder with neonatal-onset involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase OR
  - b. Urea cycle disorder with late-onset and history of hyperammonemic encephalopathy involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase AND
2. The requested dose is within the FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist (e.g., geneticist, metabolic disorders) or the prescriber has consulted with a specialist

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Voriconazole PA

**Drug Name(s)**

Voriconazole

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindication(s) to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of invasive *Aspergillus* OR

B. Patient has an infection caused by *Scedosporium apiospermum* or *Fusarium* species OR

C. Patient has a diagnosis of esophageal candidiasis or candidemia in nonneutropenic patient AND patient has tried fluconazole or an alternative antifungal agent OR patient has a documented intolerance, FDA labeled contraindication(s), or hypersensitivity to fluconazole or an alternative antifungal agent OR

D. Patient has a diagnosis of blastomycosis AND patient has tried itraconazole OR patient has a documented intolerance, FDA labeled contraindication(s), or hypersensitivity to itraconazole OR

E. The requested agent is being prescribed for prophylaxis of invasive *Aspergillus* or *Candida* AND patient is severely immunocompromised, such as a hematopoietic stem cell transplant [HSCT] recipient, or hematologic malignancy with prolonged neutropenia from chemotherapy, or is a high-risk solid organ (lung, heart-lung, liver, pancreas, small bowel) transplant patient, or long term use of high dose corticosteroids (greater than 1 mg/kg/day of prednisone or equivalent) OR

F. Patient has another indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

One month for esophageal candidiasis, 6 months for all other indications

**Other Criteria:**

Criteria for renewal approval require BOTH of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of invasive *Aspergillus*, *Scedosporium apiospermum*, *Fusarium*, esophageal candidiasis, candidemia in nonneutropenic patient or blastomycosis and patient has continued indicators of active disease (e.g., continued radiologic findings, positive cultures, positive serum galactomannan assay for *Aspergillus*) OR

B. The requested agent is being prescribed for prophylaxis of invasive *Aspergillus* or *Candida* and patient continues to be severely immunocompromised, such as a hematopoietic stem cell transplant [HSCT] recipient, or hematologic malignancy with prolonged neutropenia from chemotherapy, or is a high-risk solid organ (lung, heart-lung, liver, pancreas, small bowel) transplant patient, or long term use of high dose corticosteroids (greater than 1 mg/kg/day of prednisone or equivalent) OR

C. BOTH of the following:

- i. Patient has another indication that is supported in CMS approved compendia for the requested agent
- AND
- ii. Patient has shown clinical benefit with the requested agent



**Prior Authorization Group Description:**

Vosevi PA

**Drug Name(s)**

Vosevi

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of hepatitis C confirmed by serological markers AND
2. Prescriber has screened the patient for current or prior hepatitis B viral (HBV) infection and if positive, will monitor the patient for HBV flare-up or reactivation during and after treatment with the requested agent AND
3. The requested agent will be used in a treatment regimen and length of therapy that is supported in FDA approved labeling or AASLD/IDSA guidelines for the patient's diagnosis and genotype AND
4. The dosing of the requested agent is within the FDA labeled dosing or supported in AASLD/IDSA guideline dosing for the requested indication AND
5. If genotype 1, the patient's subtype has been identified and provided

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, hepatologist or infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Duration of therapy: Based on FDA approved labeling or AASLD/IDSA guideline supported

**Other Criteria:**

**Prior Authorization Group Description:**

Vyndaqel PA

**Drug Name(s)**

Vyndaqel

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) AND
2. The requested agent will be used to reduce cardiovascular mortality and cardiovascular-related hospitalization AND
3. Patient will NOT be using the requested agent in combination with another tafamidis agent for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) AND
3. The requested agent will be used to reduce cardiovascular mortality and cardiovascular-related hospitalization AND
4. Patient has had clinical benefit with the requested agent AND
5. Patient will NOT be using the requested agent in combination with another tafamidis agent for the requested indication

**Age Restriction:**

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cardiologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Wakix PA

**Drug Name(s)**

Wakix

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of narcolepsy with cataplexy OR

B. Patient has a diagnosis of excessive daytime sleepiness associated with narcolepsy AND BOTH of the following:

i. ONE of the following:

1. Patient has tried and had an inadequate response to modafinil or armodafinil OR

2. Patient has an intolerance or hypersensitivity to modafinil or armodafinil OR

3. Patient has an FDA labeled contraindication to modafinil or armodafinil AND

ii. ONE of the following:

1. Patient has tried and had an inadequate response to ONE standard stimulant agent (e.g., methylphenidate) OR

2. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE standard stimulant agent (e.g., methylphenidate) OR

3. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE standard stimulant agent (e.g., methylphenidate)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of narcolepsy with cataplexy OR

B. Patient has a diagnosis of excessive daytime sleepiness associated with narcolepsy AND

3. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is 18 years of age or over

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Xgeva PA

**Drug Name(s)**

Xgeva

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindication(s) to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. ONE of the following:

A. Patient has a diagnosis of multiple myeloma AND ALL of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. ONE of the following:

1. Patient has tried and failed zoledronic acid (Zometa) OR

2. Patient has a documented intolerance, FDA labeled contraindication or hypersensitivity to zoledronic acid (Zometa) AND

iii. ONE of the following:

1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR

2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR

3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR

B. Patient has a diagnosis of prostate cancer AND ALL of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. Patient has bone metastases AND

iii. ONE of the following:

1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR

2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR

3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR

Criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

C. Patient has a solid tumor cancer diagnosis (e.g., thyroid, non-small cell lung, kidney cancer, or breast cancer) AND ALL of the following:

- i. The requested agent will be used for the prevention of skeletal-related events AND
- ii. Patient has bone metastases AND
- iii. ONE of the following:
  - 1. Patient has tried and failed zoledronic acid (Zometa) OR
  - 2. Patient has a documented intolerance, FDA labeled contraindication or hypersensitivity to zoledronic acid (Zometa) AND
- iv. ONE of the following:
  - 1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
  - 2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
  - 3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR
- D. Patient has a diagnosis of giant cell tumor of bone AND ONE of the following:
  - i. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
  - ii. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
  - iii. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR
- E. Patient has a diagnosis of hypercalcemia of malignancy AND ONE of the following:
  - i. Patient has tried and failed zoledronic acid (Zometa) OR
  - ii. Patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to zoledronic acid (Zometa) AND
- 2. ONE of the following:
  - A. Patient is NOT receiving concomitant Prolia (denosumab) therapy within the past 90 days OR
  - B. Patient will discontinue the current Prolia (denosumab) therapy prior to initiating therapy with the requested agent AND
- 3. The requested dose is within the FDA labeled dosing for the requested indication

Part B before Part D Step Therapy

Applies only to beneficiaries enrolled in an MA-PD plan

**Prior Authorization Group Description:**

Xifaxan PA

**Drug Name(s)**

Xifaxan

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindication(s) to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has ONE of the following:

a. A diagnosis of irritable bowel syndrome with diarrhea (IBS-D) OR

b. A diagnosis of hepatic encephalopathy [reduction in risk of overt hepatic encephalopathy (HE) recurrence] OR

c. BOTH of the following:

i. A diagnosis of traveler's diarrhea (TD) AND

ii. The traveler's diarrhea is caused by noninvasive strains of Escherichia coli

**Age Restriction:**

For diagnosis of traveler's diarrhea (TD), patient is 12 years of age or over

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Xolair PA

**Drug Name(s)**

Xolair

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. ONE of the following:

A. Patient has a diagnosis of moderate to severe persistent asthma AND ALL of the following:

i. If the patient is 6 to less than 12 years of age AND BOTH of the following:

a. Patient's pretreatment IgE level is 30 IU/mL to 1300 IU/mL AND

b. Patient's weight is 20 kg to 150 kg AND

ii. If the patient is 12 years of age or over AND BOTH of the following:

a. Patient's pretreatment IgE level is 30 IU/mL to 700 IU/mL AND

b. Patient's weight is 30 kg to 150 kg AND

iii. Allergic asthma has been confirmed by positive skin test or in vitro reactivity test (RAST) to a perennial aeroallergen AND

iv. Patient has ONE of the following:

a. Frequent severe asthma exacerbations requiring two or more courses of systemic corticosteroids (steroid burst) within the past 12 months OR

b. Serious asthma exacerbations requiring hospitalization, mechanical ventilation, or visit to the emergency room or urgent care within the past 12 months OR

c. Controlled asthma that worsens when the doses of inhaled or systemic corticosteroids are tapered OR

d. Patient has a baseline Forced Expiratory Volume (FEV1) that is less than 80% of predicted AND

v. ONE of the following:

a. Patient is NOT currently being treated with the requested agent AND is currently treated with a maximally tolerated inhaled corticosteroid (ICS) OR

b. Patient is currently being treated with the requested agent AND ONE of the following:

1. Patient is currently being treated with an inhaled corticosteroid that is adequately dosed to control symptoms OR

2. Patient is currently being treated with a maximally tolerated inhaled corticosteroid OR

c. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to an inhaled corticosteroid AND

Initial criteria continues: see Other Criteria

**Age Restriction:**

For diagnosis of moderate to severe persistent asthma, patient is 6 years of age or over. For diagnosis of chronic idiopathic urticaria, patient is 12 years of age or over. For diagnosis of nasal polyps, patient is 18 years of age or over.

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, immunologist, otolaryngologist, pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be 6 months for initial, 12 months for renewal

**Other Criteria:**

vi. ONE of the following:

a. Patient is currently being treated with ONE of the following:

1. A long-acting beta-2 agonist (LABA) OR
2. A leukotriene receptor antagonist (LTRA) OR
3. A long-acting muscarinic antagonist (LAMA) OR
4. Theophylline OR

b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to a LABA, LAMA, LTRA, or theophylline OR

B. Patient has a diagnosis of chronic idiopathic urticaria AND BOTH of the following:

i. Patient has had over 6 weeks of hives and itching AND

ii. ONE of the following:

- a. Patient has tried and had an inadequate response to maximum tolerable H1 antihistamine therapy OR
- b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to H1 antihistamine therapy OR

C. Patient has a diagnosis of nasal polyps AND BOTH of the following:

i. ONE of the following:

- a. Patient has tried and had an inadequate response to an intranasal corticosteroid OR
- b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to an intranasal corticosteroid AND

ii. ONE of the following:

- a. The requested agent will be used in combination with an intranasal corticosteroid OR
- b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to an intranasal corticosteroid AND

2. Patient will NOT be using the requested agent in combination with Dupixent or an injectable Interleukin 5 (IL-5) inhibitor (e.g., Cinqair, Fasenna, Nucala) for the requested indication AND

3. The requested dose is within the FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of moderate to severe persistent asthma AND ALL of the following:

i. Patient's weight is within the FDA indicated range for their age (i.e., 20 kg to 150 kg for patients age 6 to less than 12 years and 30 kg to 150 kg for patients 12 years of age or over) AND

ii. Patient has had clinical benefit with the requested agent AND

iii. ONE of the following:

a. Patient is currently being treated with standard therapy (such as a combination of an ICS, LABA, LAMA, LTRA, theophylline, oral corticosteroid or an oral beta-2 agonist tablet) OR



- b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to a standard therapy OR
- B. Patient has a diagnosis of chronic idiopathic urticaria AND the following:
  - a. Patient has had clinical benefit with the requested agent OR
- C. Patient has a diagnosis of nasal polyps AND the following:
  - a. Patient has had clinical benefit with the requested agent AND
- 3. The requested agent will NOT be used in combination with Dupixent or an injectable interleukin 5 (IL-5) inhibitor (e.g., Cinqair, Fasenra, Nucala) for the requested indication AND
- 4. The requested dose is within the FDA labeled dosing for the requested indication

**Prior Authorization Group Description:**

Xywav PA

**Drug Name(s)**

Xywav

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of narcolepsy with cataplexy OR

B. Patient has a diagnosis of narcolepsy with excessive daytime sleepiness AND BOTH of the following:

i. ONE of the following:

a. Patient is under 18 years of age OR

b. ONE of the following:

1. Patient has tried and had an inadequate response to modafinil or armodafinil OR

2. Patient has an intolerance or hypersensitivity to modafinil or armodafinil OR

3. Patient has an FDA labeled contraindication to modafinil or armodafinil AND

ii. ONE of the following:

a. Patient has tried and had an inadequate response to ONE standard stimulant agent (e.g., methylphenidate) OR

b. Patient has an intolerance or hypersensitivity to ONE standard stimulant agent (e.g., methylphenidate) OR

c. Patient has an FDA labeled contraindication to ONE standard stimulant agent (e.g., methylphenidate) OR

C. Patient has a diagnosis of idiopathic hypersomnia

**Age Restriction:**

For a diagnosis of narcolepsy with cataplexy or narcolepsy with excessive daytime sleepiness: Patient is 7 years of age or over. For a diagnosis of idiopathic hyperinsomna: Patient is 18 years of age or over.

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**